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Abstract 
Coronary artery disease (CAD) is a leading cause of mortality worldwide, 
despite great efforts in designing several risk stratification models for more 
effective prevention of related complications and creating more advanced 
treatment methods. Furthermore, the average age of affected patients 
observed recently, is significantly lower compared to previous decades and 
potential complications remain devastating. In recent years, the global 
thrombosis test (GTT), which is a novel test assessing clot 
formation/thrombosis and subsequent endogenous thrombolysis (ET) under 
physiological conditions, has been used in several studies of patients with acute 
coronary syndrome (ACS), providing us with valuable information. This test is 
unique, as it is currently the only test of its kind, able to assess individual ET, 
which according to these studies can predict cardiovascular death and non-
fatal myocardial infarction (MI) in ACS patients. However, stable angina 
patients and patients with MI undergoing primary percutaneous coronary 
intervention (PPCI), the most critically affected CAD patients, had not been 
previously investigated, therefore this enabled us to design a study 
investigating fields never been previously explored, with the prospect of 
presenting data that could stimulate further research and enhance future 
management of patients with cardiovascular disease. We successfully 
demonstrated that individual ET status can predict major adverse 
cardiovascular events (MACE) following PPCI. Furthermore, we showed that 
increased individual platelet reactivity before PPCI, is related to non-fatal MI, 
which had not been shown in previous studies of global thrombosis. In the 
group of non-ST elevation myocardial infarction (NSTEMI) patients, we 
observed significant relationship between ET and peak Troponin level, which is 
a marker of the size of myocardial damage, resulting from lasting coronary 
thrombus. Finally, we demonstrated that the medication vorapaxar, which is a 
direct thrombin inhibitor, can enhance ET and could be proven to be beneficial 
when administered in certain patients, for the prevention of future adverse 
cardiovascular events. The main limitation identified in all sub-studies, was the 
small patient number, therefore in view of the positive results demonstrated in 
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our study, larger scale studies should be carried out, aiming to reinforce the 
vital role of global thrombosis assessment in patients with CAD. 
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Background 
Introduction/ Study aims 
 
Ischaemic heart disease (IHD) is often considered as an exclusive problem of 
wealthy western countries, in which stressful lifestyle and careless diet promote 
coronary artery disease (CAD). According to recent epidemiological studies 
though, IHD is the leading cause of death in developing countries as well, where 
it accounts for nearly 30% of all deaths (Finegold, Asaria, & Francis, 2013). 
Furthermore in spite of the fact that it has always been regarded as the disease 
of old age, recently the average age of patients with cardiac events has been 
decreasing dramatically (Finegold et al., 2013). 
The most worrying feature though, is the fact that it is still the leading cause of 
death worldwide, despite great advances demonstrated in both prevention and 
treatment. The role of endogenous thrombolysis (ET) has recently been shown 
to be an important predictor of major adverse cardiovascular event (MACE) in 
patients with ACS and end-stage renal failure, according to studies of global 
thrombosis, using a novel platelet function test (PFT), called the global 
thrombosis test (GTT)(Saraf, Christopoulos, Salha, Stott, & Gorog, 
2010)(Sharma et al., 2012), which is valuable information and the stimulus for 
designing our study. 
 
The primary purpose of our study is to investigate whether global thrombosis 
status assessed by the GTT, can predict future adverse events following PCI, 
which is the main treatment of CAD. Despite great efforts for development of 
better stent structure and stent implantation techniques, as well as for 
optimization of pharmacotherapy following PCI with antiplatelet therapy and 
CVD risk factor modification, adverse events still occur, they are life threatening 
and can cause psychological impact to patient who survive them and their 
families. Furthermore, for each adverse event, there is a significant financial 
charge to the NHS, which is currently under a lot of pressure. The prospect of 
identifying high risk patients for adverse events following PCI by routinely using 
the GTT, would revolutionize future management of CAD.  
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Following a literature review on the timing of PPCI in STEMI patients, which is 
a very important topic, as it refers to the most clinically unstable patients with 
CAD, we believe that investigation of the relationship between delay in PPCI 
coronary revascularization and enhanced thrombogenicity or delayed ET, could 
potentially provide us with valuable information that could reinforce our results 
supporting the main purpose of the study. 
 
Antiplatelet agent resistance and consequent stent thrombosis is the reason for 
development of more pharmacotherapy, aiming for more efficient prevention of 
thrombosis. However, development of medication enhancing ET is something 
that has never been previously proposed and definitely something worth 
investigating. Vorapaxar is an antiplatelet medication recently investigated in 
two large trials (Leonardi et al., 2013) (Cavender et al., 2015), including the UK 
and specifically our cardiology centre. We obtained permission from the trial 
organisers to investigate the effect of this medication on global thrombosis and 
particularly the effect on ET using the GTT. Results of this sub-study have been 
included and discussed in the final chapter of thesis. 
Coagulation cascade 
Coagulation cascade is a protective measure in response to blood vessel 
damage. It consists of two pathways, the extrinsic or tissue factor pathway and 
the intrinsic or contact activation pathway leading to the final common pathway 
resulting in a stable fibrin clot (Lefkowitz, n.d.). 
The role of the extrinsic pathway is rapid production of thrombin. Initially factor 
VII comes into contact with tissue factor (TF) following blood vessel damage, 
forming TF-VIIa complex. Factor VII is itself activated by thrombin and factors 
XIa, XII, Xa. 
TF-VIIa complex then activates factors IX and X. 
Factor Xa with the aid of its co-factor Va form the prothrombinase complex, 
which activates prothrombin to thrombin (Lefkowitz, n.d.). 
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Intrinsic pathway 
The intrinsic pathway begins with the formation of the primary complex on 
collagen, pre-kallikrein and factor XII or Hageman factor. Then pre-kallikrein is 
converted into kallikrein and factor XII into XIIa. Subsequently factor XIIa 
converts factor XI into XIa which in turn activates factor IX to form the tenase 
complex with the aid of the co-factor VIIIa. Eventually tenase complex activates 
factor X to Xa (Lefkowitz, 2006). 
In the final common pathway thrombin serves several tasks. It primarily 
converts fibrinogen to fibrin monomer, which is the main building element of the 
blood clot. Furthermore it activates factors VIII, V and finally factor XIII to form 
fibrin polymers from activated monomers (Lefkowitz, 2006). For example, 
cross-linking by activated factor XIII, enhances fibrin elasticity, as well as 
promotes resistance to fibrinolysis. Factor XIIIa also cross-links a2-antiplasmin, 
plasminogen activator inhibitor-2 and thrombin-activatable fibrinolysis inhibitor 
(TAFI) to fibrin, further enhancing resistance to fibrinolysis (Undas & Ariëns, 
2011). 
This process is facilitated by different co-factors and regulators. One regulator 
is Protein C, which is a physiological anticoagulant. It is activated by thrombin 
into activated Protein C, which in combination with Protein S degrade factors 
Va and VIIIa (Lefkowitz, 2006). 
Deficiency in any of these factors and co-factors results in coagulation 
problems or bleeding disorders. Furthermore most of the pharmacological 
agents used nowadays, target different parts of the cascade in order to prevent 
thrombosis (Lefkowitz, 2006).  
Extrinsic pathway 
The extrinsic pathway is the first step in plasma mediated haemostasis and it 
is activated by TF, which is expressed in the sub-endothelial tissue. Following 
a vascular insult, exposed TF binds with factor VIIa and calcium, in order to 
trigger the conversion of factor X to Xa, which then changes factor II into 
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thrombin. Thrombin promotes coagulation in two ways. Firstly, it changes 
fibrinogen to fibrin and secondly turns factor XIII into XIIIa, which in turn forms 
fibrin polymer into cross-linked clot (Lefkowitz, 2006). 
Figure 1. Coagulation pathways 
 
 
 
 
Thrombosis 
Endothelial dysfunction in thrombosis 
Thrombosis plays a crucial role in the pathogenesis of ACS. Following many 
years of research it is believed that it is a multifactorial phenomenon that 
manifests according to changing physiological conditions (Chung et al., 2003). 
 11 
Since atherosclerotic plaques arise from the coronary artery endothelium, one 
should first investigate the potential involvement of endothelial dysfunction in 
atherothrombotic events. Healthy endothelium should promote vasodilation 
and exhibit anti-platelet as well as pro-fibrinolytic properties, unlike abnormal 
endothelium in ACS, in which we observe the exact opposite 
pathophysiological features. Several factors have been suggested as possible 
contributors to endothelial dysfunction, such as the presence of higher levels of 
circulating von Willebrand factor (vWF) and lower levels of tissue factor 
pathway inhibitor in ACS patients. vWF is a specific marker for endothelial cells 
and it is known to promote platelet adhesion to diseased vessel wall and to 
activated endothelial cells, thus favoring thrombogenesis (Chung et al., 2003). 
Factors promoting thrombosis 
Oxidative stress is another factor eventually promoting thrombosis. It is 
achieved by both reducing nitric oxide bioavailability and promoting prostacyclin 
production by endothelial cells, with resulting inability to inhibit inflammatory 
and subsequently prothrombotic response within an atherosclerotic lesion, thus 
increasing ACS risk (Libby & Theroux, 2005). 
Platelets play a key role in the pathogenesis of ACS. Exposure of the sub-
endothelial matrix resulting from plaque rupture is a trigger for platelet adhesion 
at first, followed by platelet activation which is facilitated by inflammatory cells, 
metalloproteinases, thrombin, thromboxane A2 (TXA2), platelet activating 
factor (PAF), adenosine 5-diphosphate (ADP), epinephrine and serotonin. 
Thrombogenesis can also be induced by shear forces within the unstable 
plaque due to stimulating prostaglandin release (Libby & Theroux, 2005). 
The bond though between a ruptured plaque and platelets is through the 
complex interaction between vWF, collagen, platelet glycoproteins Ib and after 
activation of the platelet surface IIb/IIIa receptor, which is the a binding site for 
fibrinogen binding. Finally b3 integrins are responsible for the definite adhesion 
(Libby & Theroux, 2005). 
Lately there has been emerging evidence of the crucial role of ADP in 
thrombosis by acting on P2X1, P2Y1 and P2Y12 receptors which are situated 
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on the platelet surface, eventually triggering fibrinogen binding on the platelet 
surface glycoprotein IIb/IIa receptor, causing platelet adhesion and aggregation 
(Libby & Theroux, 2005). 
It has recently been suggested that PCI patients are at risk of future ischaemic 
events from stent thrombosis, due to procedure-related platelet activation, 
especially following ACS, when platelet hyper-reactivity and enhanced 
thrombin formation is observed (Libby & Theroux, 2005). 
Tissue factor (TF) also triggers thrombosis within coronary lesions, where TF  
concentrations have been found to be very high. Furthermore its levels are also 
increased in circulating blood of patients with unstable angina, as are the levels 
of thrombin, promoting the adverse thrombotic events. Under normal 
circumstances tissue plasminogen activator (t-PA) and urokinase are inhibited 
by plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2, 
whereas plasmin is inhibited by circulating alpha-2-antiplasmin. These two 
mechanism are interrupted during the thrombotic process,  resulting in lower 
levels of t-PA and higher levels of PAI-1, thus impairing endogenous 
thrombolysis (Libby & Theroux, 2005). 
Inflammation The role of inflammation is extremely important in the 
pathogenesis of atherosclerosis, from development and progression of 
atheroma to plaque instability, as well as in restenosis following angioplasty. 
 
This process is initiated by the adherence of circulating leucocytes to injured 
endothelium via several classes of adhesion molecules, such as vascular 
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) 
and selectins, that co-operate with cytokines in order to enable adherence. 
Subsequently, chemoattractant cytokines promote transmigration of 
inflammatory cells into the sub-endothelial space (Libby, 2012)(Zakynthinos & 
Pappa, 2009). 
 
At a later stage, low-density lipoproteins (LDL) bind to monocyte-derived 
macrophages forming lipid-laden foam cells, the main constituent of the fatty 
streak, which is a key feature of the advanced atherosclerotic plaque. 
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At the same time mononuclear cells release interleukin-1 (IL-1) and interleukin-
6 (IL-6) attracting more inflammatory cells, resulting in even more uptake and 
oxidation of LDL (Libby, 2012)(Zakynthinos & Pappa, 2009). 
Furthermore these cytokines stimulate smooth muscle cell proliferation and 
development of the collagenous fibrous cap. The synthesis and degradation of 
collagen and subsequently the stability of the fibrous cap is dynamically 
controlled by inflammation (Libby, 2012)(Zakynthinos & Pappa, 2009). 
 
Inflammatory cells, such as activated T cells, produce interferon gamma (INFγ) 
which causes a decrease in the production of collagen by smooth muscle cells. 
Additionally activated macrophages produce matrix metalloproteinases 
(MMPs) that promote collagen destruction, thus promoting fibrous cap 
instability and subsequently plaque rupture. 
Following plaque rupture there is direct contact between the pro-coagulant lipid 
core and the blood, favouring further inflammatory reactions leading to platelet 
activation, coagulation cascade activation, vasomotor dysfunction and 
coronary lumen occlusion leading to myocardial infarction (Libby, 
2012)(Zakynthinos & Pappa, 2009). 
 
Inflammatory response is also an important factor in the development of neo-
intimal thickening and restenosis following PCI. 
The injury caused by balloon angioplasty and stent insertion to the coronary 
wall can cause platelet activation and subsequent leukocyte attraction to the 
site. There is evidence from published research, demonstrating that PCI causes 
activation and up-regulation of Mac-1 on the surface of neutrophils, promoting 
in-stent restenosis within 48 hours of stenting (Libby, 2012)(Zakynthinos & 
Pappa, 2009). 
 
Since inflammation plays such an important role in atherogenesis in coronary 
arteries, as well as in restenosis post-PCI, several research studies have 
investigated potential inflammatory markers as biomarkers for cardiovascular 
risk assessment. 
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C-reactive protein (CRP) is the most investigated inflammatory marker of 
cardiovascular disease. It has been suggested that CRP levels correlate with 
the presence of plaque rupture as evidenced by intravascular ultrasound 
(Sadeghi, Pourmoghaddas, Tavasoli, & Roohafza, 2010). Furthermore, 
increased temperature, a feature of unstable coronary plaque, detected by 
invasive thermogenetic catheter, was associated with higher levels of CRP 
(Sadeghi et al., 2010). Finally several studies have suggested that this marker 
could be a predictor of adverse outcomes following MI (Zakynthinos & Pappa, 
2009) (Ridker, 2003). The THROMBO study, one of the biggest studies 
assessing the role of CRP, recruiting 1045 post-MI patients, despite 
demonstrating association of the marker with recurrent coronary events, it failed 
to prove that CRP is an independent factor of events (Zakynthinos & Pappa, 
2009).  
 
Procedural determinants of stent thrombosis 
Since their introduction, stents have been widely used to treat patients with 
coronary artery disease, with around 2.5 million being implanted yearly. Despite 
improvements in stent design and implantation techniques and more effective 
anti-platelet regimes, stent thrombosis remains an issue, due to its devastating 
consequences (short-term mortality up to 25%). The wide variability observed 
in its estimated incidence shows that stent thrombosis should be regarded as 
a multifactorial phenomenon. 
Several studies have identified important clinical, angiographic and procedural 
determinants of stent thrombosis, however most of these studies had 
limitations, such as their small sample size, variation in the definition of stent 
thrombosis and overlooking less frequently occurring risk factors that could not 
be explored. Additionally the majority of them did not focus on differences in 
underlying pathophysiological mechanisms between various indications of PCI 
(stable vs ACS patients and early vs late thrombosis) (D’Ascenzo et al., 2013) 
(Neville Kukreja et al., 2009). 
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The metal stent material, the polymer and the eluted drug are potential stent-
related causes of thrombosis. The purpose of the eluted drugs (sirolimus, 
paclitaxel, zotarolimus and everolimus), is to inhibit cell cycle, thus delaying 
neo-intimal growth, with migration and proliferation of vascular smooth muscle 
cells. Since PCI is known to cause endothelial destruction and cell cycle 
inhibitors prevent re-endothelialisation, these can predispose to thrombosis 
(Neville Kukreja et al., 2009). 
The presence of a polymer in the vessel wall could induce local hypersensitivity 
which could be thrombogenic. Likewise exposure of stent struts, which is 
considered as pro-inflammatory, can cause eventual thrombosis. It is thought 
that this phenomenon is more often seen with drug eluting stents (DES) due to 
the delay in endothelial re-growth and consequently coverage of struts. 
Furthermore poor procedural techniques such as stent under-deployment can 
lead to thrombosis. Finally thrombosis is commoner in longer stent implantation 
and stented bifurcations, in which use of DES is preferable (Neville Kukreja et 
al., 2009). 
 
Antiplatelet resistance causing stent thrombosis 
Apart from stent-related causes of thrombosis there are also patient-related 
causes, such as anti-platelet therapy resistance (Aspirin+/- Clopidogrel 
resistance), malabsorption and non-compliance to pharmacotherapy 
(Casterella, n.d.). 
Anti-platelet duration following PCI has been a hot topic for discussion, hence 
the American College of Cardiology as well as the American Heart Association 
recommended use of dual anti-platelet therapy for one year in patients without 
major risk of bleeding, as a measure for adequate decrease in thrombosis 
incidence (Casterella, n.d.) (O’Gara et al., 2013). 
Resistance to either one or both anti-platelet agents following PCI implantation, 
is an issue that has recently emerged and it is regarded as very serious. 
According to published data among the patients treated with coronary stents, 
15% are resistant to Aspirin and 24% are resistant to Clopidogrel, with 50% of 
Aspirin-resistant patients exhibiting reduced response to Clopidogrel as well 
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(Dupont, Gabriel, & Cohen, 2009). 
Clopidogrel’s target is the P2Y12 receptor on the platelet surface, which it binds 
irreversibly. Variation in the drug’s response depends on polymorphism of the 
hepatic CYP3A4 pathway that can affect the production of active drug, thus 
reducing its effect on binding the platelet receptor and inhibiting platelet 
function. Apart from genetic variability, there are also other reasons for reduced 
drug activity, such as interaction with other drugs, low intestinal absorption and 
variation in loading and maintenance doses (Dupont et al., 2009). 
Aspirin targets platelet cyclooxygenase-1 (COX-1), which binds irreversibly in 
order to exhibit its anti-platelet purpose. Resistance to Aspirin is a multifactorial 
phenomenon and probably the most important contributory factor is poor 
medication adherence. Another potential cause for resistance is the adverse 
effect of underlying inflammatory process that can promote faster regeneration 
of platelets and COX-1 at a rate that a single dose of Aspirin is not effective. 
The full mechanism of Aspirin resistance phenomenon though is not fully 
understood and it is a subject of ongoing research (Dupont et al., 2009). 
Stent thrombosis incidence 
A large study in the Netherlands (N Kukreja et al., 2009) investigated the 
incidence of stent thrombosis in 5816 patients undergoing PCI, amongst whom 
2248 had a bare metal stent (BMS) and the remaining paclitaxel or sirolimus 
DES. Additionally these patients were categorized according to their 
presentation into patients with stable angina, unstable angina (UA)/non-ST 
elevation MI (NSTEMI) and ST elevation MI (STEMI). 
The primary end point was stent thrombosis, defined as angiographically 
documented thrombus with Thrombolysis In Myocardial Infarction flow grade 0 
or 1, accompanied by acute symptoms (consistent with the Academic Research 
Consortium classification of definite stent thrombosis)  
The timing of stent thrombosis was classified as follows (Press, 2015):  
1. Early (within a month from implantation) 
2. Late (between one month and a year from implantation) 
3. Very late (more than one year from implantation) 
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The results showed lower incidence in overall thrombosis in stable angina 
patients, regardless of the type stent inserted, compared to ACS patients. 
Amongst ACS patients, there was no significant difference observed between 
UA/NSTEMI and STEMI patients. In ACS patients with DES there was a non-
significant trend towards very late thrombosis, however the incidence of early 
and late thrombosis did not reach statistical significant according to stent type. 
Surprisingly, higher mortality rates were observed in stable patients rather than 
in ACS patients. Additionally, while in the ACS group mortality was more 
common with early stent thrombosis, in stable patients mortality was 
independent of timing of thrombosis (N Kukreja et al., 2009). 
The Dutch stent thrombosis registry has identified all the previously mentioned 
risk factors for stent thrombosis with the addition of two independent factors, 
the presence of malignancy, an intermediate lesion >50% and <70% proximal 
to the treated culprit lesion during index procedure (van Werkum et al., 2009). 
New antiplatelet agents 
Prasugrel is rapidly absorbed following oral administration and converted to its 
active metabolite, reaching peak concentrations within 30 minutes. It has more 
rapid onset of action and achieves more consistent and complete inhibition of 
ADP-induced platelet aggregation compared to Clopidogrel, mainly due to 
hepatic conversion into its active metabolite in one step rather than two-step 
hepatic conversion seen in Clopidogrel’s metabolism (Cheng, 2013). 
Clinical outcomes data for Prasugrel  comes mainly from phase III TRITON-
TIMI 38 (Matte-martyn et al., 2011), where 13608 patients with ACS and 
planned PCI were randomized to receive either Clopidogrel 300mg loading 
dose followed by 75mg daily or Prasugrel 60mg loading followed by 10mg daily 
and treated for a median of 14.5 months. 
Patients randomized to Prasugrel had fewer primary end-point events 
compared with Clopidogrel. There was reduction in clinical ischaemic events 
as there was notable reduction in MI and urgent target vessel revascularisation. 
However prasugrel-randomised patients showed significantly higher tendency 
for major bleeding requiring transfusion, as well as higher tendency for minor 
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bleed.  
A sub-analysis of the trial showed one of the most interesting qualities of 
Prasugrel which is the significant reduction in in-stent restenosis (ISR), 
regardless of the type of stent (Cheng, 2013). 
Ticagrelor  is a cyclopenthyl-triazolopyrimidine, a new class of anti-platelet 
agents, which is a selective antagonist of the P2Y12 receptor and inhibits ADP-
mediated platelet response. Unlike Clopidogrel and Prasugrel its inhibitory 
activity does not require metabolic activation, despite the fact that its active 
metabolite also demonstrates P2Y12 receptor antagonism activity (Cheng, 
2013). 
The PLATO study (Lindholm et al., 2014) demonstrates the efficacy and 
tolerability of the use of Ticagrelor in ACS compared to that of Clopidogrel. In 
this study, 18624 patients admitted to hospital within 24h of an ACS were 
randomized to either receive Ticagrelor 180mg loading dose followed by 90mg 
twice daily or Clopidogrel 300 to 600mg loading dose followed by 75mg daily 
thereafter. 
The outcome was that treatment with Ticagrelor significantly reduced the rate 
of death from vascular causes, MI or stroke, without an increase in the rate of 
overall major bleeding, however there was an increase in the rate of non-
procedure related major bleeding (Cheng, 2013). 
Future strategies for reducing thrombotic risk 
Prevention of stent thrombosis should be guided by focusing on the main 
determinants of this serious complication. New stents in respects to both design 
and drug elution, have significantly contributed towards a dramatic reduction in 
stent thrombosis. The four-year follow-up results of the ABSORB trial looking 
at ischaemia driven MACE following bioabsorbable everolimus-eluting stent in 
patients with CAD, were very optimistic as no stent thrombosis was reported 
during the study period (Press, 2015).  
Simultaneously, accompanying advances in pharmacotherapy, as well as 
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increase in its duration following PCI, have also reduced the incidence of 
thrombosis. Attention should not only focus on the efficacy of medications, but 
also on side effects such as bleeding, the result of which can be devastating for 
the affected patients. 
Complexity of lesions and subsequent difficulties in performing PCI, is another 
risk factor for thrombosis. As mentioned earlier, stent malapposition can 
predispose to thrombosis, therefore it was suggested that surveillance for high 
risk cases is indicated with the aid of intravascular ultrasound or optical 
coherence tomography (Press, 2015). Published results of a study investigating 
bioabsorbable scaffold thrombosis via angiography and optical coherence 
tomography, prove that suboptimal stent insertion, under-expansion and 
malapposition are responsible for both early and late thrombosis. Furthermore, 
early antiplatelet agent discontinuation seems to be another contributor, 
particularly in late events. However, stent thrombosis for the above reasons are 
highly preventable (Karanasos, 2015). 
The need for assessing and identifying patients following PCI at risk of 
thrombosis, is of great importance.  
Finally, regular follow-up of post-PCI patients with view to promote drug 
compliance and risk factor modification as part of secondary prevention should 
be considered as an issue of equal importance. 
 
 
Endogenous thrombolysis 
Endogenous Thrombolysis mechanism 
Tissue plasminogen activator is stored in large amounts intra-cellularly as well 
as in steady amounts intra-vascularly, where it circulates in 2 forms, one active 
and one in complex with PAI-1 and PAI-2. It is estimated that the active form of 
t-PA makes up about 20% of the total (Kovacs, Gorog, & Yamamoto, 2006) . 
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Release of t-PA can be stimulated by several factors involved in the process 
thrombosis like thrombin and PAF. Therefore endogenous release of t-PA is a 
mechanism of vital clinical importance as it is the basis of ET promoting 
spontaneous re-canalisation in occluded coronary arteries. However, apart 
from t-PA, PAI-1 and PAI-2 are also released from endothelial cells in response 
to ischaemia and it is still not known what drives the balance between fibrinolytic 
stimulators and inhibitors in this situation, as ET status differs among different 
individuals (Kovacs, Gorog, & Yamamoto, 2006). 
Thrombosis vs Fibrinolysis 
Several mechanisms have been identified from experimental studies to 
influence shift of this balance towards either fibrinolysis or inhibition. 
The first mechanism described involves polymorphonuclear leucocytes which 
tend to accumulate within thrombi at an early stage of thrombogenesis. These 
monocytes can attack fibrin via plasminogen dependent ways (plasminogen 
activator release) and independent ways (serine protease release), thus 
favoring fibrinolysis (Kovacs et al., 2006). 
On the other hand arterial thrombi are rich in platelets and more resistant to 
lysis due to release of PAI-1 upon platelet activation. It is estimated that around 
90% of total PAI-1 in the blood is contained in platelets. Conversely, the levels 
of t-PA and t-PA/PAI-1 complex have been found to be low in thrombi, therefore 
one could postulate that this could be attributed to the imbalance between PAI-
1 levels against t-PA and t-PA/PAI-1 complex levels during ischaemia (Kovacs 
et al., 2006). 
MI is the outcome of an imbalance between the mechanism of thrombosis 
against that of spontaneous thrombolysis (Kovacs, Gorog, & Yamamoto, 2006), 
which is a potentially life saving process, but unfortunately often neglected 
when discussing the causes of atherothrombotic events. The majority of STEMI 
patients undergoing PPCI are found to have TIMI 0 flow in their culprit vessel, 
which is associated with larger myocardial damage and consequently with 
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higher morbidity and mortality rates, especially when pain-to-balloon time (PTB) 
is prolonged (Blankenship et al., 2011).  
However in the case of spontaneous lysis due to ET, even the small 
improvement in TIMI flow, could be enough to result in better clinical outcomes 
following PPCI. 
With the exception of pharmacological thrombolysis, which nowadays is not the 
mode of treatment in STEMI due to its high risk of complications (intracranial 
bleeding, reperfusion arrhythmias) and need for longer in-patient stay, current 
pharmacotherapy for both primary and secondary prevention for ACS focuses 
exclusively on the anti-thrombotic properties of medication. Currently there is 
no known pharmacological agent promoting ET, therefore one could question 
the efficiency of current medical treatment since not every determinant of ACS 
is targeted. 
Platelet function test (PFT) 
Traditional Platelet function tests 
Platelet hyper-reactivity has been identified as a potential mechanism of acute 
MI and identification of individuals exhibiting this should contribute towards 
more effective primary as well as secondary prevention. Therefore the need for 
a novel test that could accurately assess platelet activity is crucial in our search 
for strategies to reduce the incidence of IHD. However none of the currently 
used PFTs stands out as superior to others for its purpose (Gorog & Fuster, 
2013). 
Over the last decades several PFTs have been introduced, however they have 
all shown limitations, such as complexity in their use (both to perform and to 
evaluate) and delay in providing us with results. Also some of the tests designed 
to assess platelet hyper-reactivity, failed to fulfill their task due to lack of 
standardization and inability to define ‘normal’ and ‘hyper-reactive’ ranges as 
well as to identify patients at risk (Gorog & Fuster, 2013). Tests employed to 
measure Aspirin resistance have provided us with conflicting results regarding 
the actual percentage of this phenomenon, up to a point where it has been 
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suggested that inadequate information may mislead physicians (Gorog & 
Fuster, 2013). 
Clopidogrel resistance is a major issue nowadays, because this medication is 
the commonest agent used along with Aspirin in patients undergoing PCI. 
Several tests have been used in order to identify Clopidogrel non-
responsiveness, however significant inconsistencies have been observed in the 
outcomes among different assays. This could be explained by the fact that 
these tests assess different aspects of platelet function. At the moment there is 
no PFT to be regarded as superior compared to others in detecting clopidogrel 
resistance (Gorog & Fuster, 2013). 
Since the usefulness of Clopidogrel in reducing the risk of MACE following ACS 
has been statistically proven, regardless of the magnitude of resistance, one 
would question the usefulness of PFTs in assessing non-responsiveness 
(Gorog & Fuster, 2013). However due to the fact that its prevalence has been 
estimated by some tests up to 33%, it would not be unreasonable to search for 
the ideal PFT that would offer accurate assessment of resistance prevalence 
as well as its involvement in post-PCI event risk. This latter task is not easy to 
be performed due to the low frequency of MACE following PCI. Therefore in 
order to demonstrate relationship between PFT and events, larger studies 
should be designed (Gorog & Fuster, 2013). 
Bleeding in response to anti-platelet agent use is another issue PFTs have 
attempted to assess. This can be achieved by assessing platelet reactivity as 
well as the number of bleeding events in response to different agonists. 
However this task can become more challenging due to attempted combination 
of anti-platelet agents for prevention of coronary events, requiring the 
assessment of response to a greater number of agonists by PFTs (Gorog & 
Fuster, 2013). 
Use of citrate-anticoagulated blood instead of native blood could be the cause 
of inconsistencies observed in the results of various tests, because different 
citrate concentrations can influence results as platelet response to agonists can 
vary. 
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Additionally, use of anti-coagulants such as heparin can alter platelet reactivity 
and impair measurement of the effect of thrombin (Gorog & Fuster, 2013). 
 
Novel platelet function tests 
 
The ideal PFT should demonstrate some qualities not been observed so far by 
any other test on the whole. Firstly, this test should be simple in its use and fast 
in providing us with results. Complex tests can be time consuming and hence 
unsuitable, especially in the acute setting, such as in STEMI situation where 
testing should not interfere with PPCI process and results are required in a 
short time. Secondly it should demonstrate accuracy and consistency. This can 
enable researchers to define ranges for risk and safety, thus promoting safety 
in future patient management. Furthermore it should be cost effective. As larger 
trials are necessary for providing statistical power, for example in obtaining 
greater number of post-PCI events, a greater number for tests will be needed, 
so we should aim for lower costs without altering test quality. This issue is also 
important as more tests are necessary for each recruited patient in an attempt 
to assess thrombosis through a patient’s hospitalization from initial event day 
until outpatient follow-up in order to investigate possible variations thrombosis 
in response to different risk factors, altering pharmacotherapy, inflammation, 
drug resistance (Gorog & Fuster, 2013). 
 
 
 
 
 
The global thrombosis test (GTT) 
 
Endogenous Thrombolysis and PFTs 
 
The catastrophic consequences of thrombosis following the sequence of 
atherosclerotic plaque rupture, platelet adhesion and activation of coagulation 
cascade, are a major cause for morbidity and mortality worldwide.  
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ET, a natural and potentially life saving defense mechanism whose purpose is 
to balance thrombosis, is unfortunately a process that has been overlooked by 
researchers, hence the absence of pharmacotherapy aiming to promote 
fibrinolysis, with the exception of fibrinolytic agents used acutely in STEMI. 
Even this treatment though has been recently overshadowed by PPCI, which 
according to current evidence has been proven to be superior than fibrinolysis 
due to a better profile demonstrated in terms of successful outcomes, reduced 
mortality and hospitalisation times. Spontaneous fibrinolysis has never been 
assessed previously, but its relevance to STEMI and its future outcomes has 
been highlighted in several published papers. Specifically, the occurrence of 
this process was confirmed by both angiographical and electrocardigraphical 
evidence and was associated with lower mortality, lower heart failure incidence 
and better future prognosis in terms of lower risk for recurrent ACS. 
A series of issues, such as the absence of a reliable PFT, as well as recognition 
of the great importance of ET in relation to IHD and its management, have led 
researchers in the manufacture of a new point-of-care test which is very simple 
in its use, aiming to assess both thrombosis and ET in the clinical setting, 
providing us with results in a short time (Saraf et al., 2010) (Sharma et al., 
2012). 
 
The Global Thrombosis Test 
 
The Global Thrombosis Test (GTT) (Montrose Diagnostics, London, United 
Kingdom) (Yamamoto, Inoue, Otsui, Ishii, & Gorog, 2014) is a novel test 
designed to simultaneously measure platelet reactivity and endogenous 
thrombolysis using native, non-anticoagulated blood. The main device has 4 
separate channels able to accommodate a single test tube each, placed in a 
vertical position. The lumens of these test tubes are designed in such a way in 
order to resemble the lumen of an atherosclerotic coronary vessel. Their distal 
end has a conical shape inside which two small ceramic balls are placed one 
on top of the other, just above the distal opening, through which blood can drip 
inside a reservoir that is a part of the plastic test tube. Optical sensors can 
detect blood flow as well as its rate by measuring the interval between 
consecutive falling blood drops into the reservoir. 
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Once blood is injected into the narrow lumen and flows through the gaps 
between the balls and the tube walls, platelet activation occurs due to shear 
forces exerted, leading to thrombin generation and subsequently thrombus 
formation, eventually obstructing blood flow completely. ‘Occlusion Time’ (OT) 
is the time between initial injection of blood in the tube until flow arrest and it is 
defined as duration between two consecutive drops exceeding 15 seconds.  
Apart from platelet reactivity that can be easily and reliably assessed in the 
clinical setting as explained above, this test demonstrates another unique 
quality, which is the ability to assess ET. The time elapsed between total 
occlusion and spontaneous flow restoration following thrombus lysis is called 
Lysis Time (LT) and it is measured in seconds. 
The manufacturer has proposed OT/LT ranges for data interpretation, however 
more evidence has been recommended for confirmation of their accuracy and 
hence their reliability: 
1. OT <80sec. (Unreliable test) 
2. OT <300sec. (Platelet hyper-reactivity) 
3. OT 300-500sec. (Normal platelet function) 
4. OT 400-800sec. (Anti-platelet/anticoagulant effect or minor bleeding 
diathesis) 
5. OT 500-700sec. (Optimal anti-platelet effect) 
6. OT >900sec. (Possible bleeding risk) 
7. LT <2000sec. (Normal spontaneous thrombolytic activity) 
8. LT 2000-4000sec. (Reduced thrombolytic activity) 
9. LT 4000-6000sec. (Markedly reduced thrombolytic activity) 
10. LT >6000sec. (No detectable thrombolytic ability) 
 
 
Figure 2. The global thrombosis test. 
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Figure 3. Platelet activation and thrombosis inside the GTT tube. 
 
 
GTT and published data 
 
Data using the GTT has been published in several papers. The two most 
important ones investigated the role of ET in ACS and End Stage Renal Failure 
(ESRF) patients respectively (Saraf et al., 2010) (Sharma et al., 2012) 
(Yamamoto et al., 2014).  
The first one (Saraf et al., 2010) demonstrated for the first time the role of ET 
both as an independent risk factor for future thrombotic events. Furthermore, 
delayed ET was identified as a strong predictor of recurrent cardiovascular 
events (death and non-fatal MI) and an LT of 3000s was estimated as THE cut-
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off value for prolongation. On the other hand no relationship was demonstrated 
between OT and MACE. The main limitations were identified and suggestions 
were proposed for future studies involving use of the GTT. In specific it was 
suggested that a bigger study should be designed, with more tests performed 
during index event hospitalization in order assess the influence of anti-platelet 
agents and inflammation on thrombosis, something that cannot be accurately 
measured with a single test. Additionally the effect of heparin was mentioned 
as a factor impairing quality of results due to its influence in the process of 
thrombosis.  
 
The second study (Sharma et al., 2012) investigating ET in ESRF patients and 
showed coinciding results with the previous one. In specific impaired ET which 
is very common in ESRF patients was proven to be a strong predictor of MACE, 
unlike OT status which was not related to future outcomes. The conclusion from 
these two studies was that ET is a phenomenon needed to be further 
investigated in a greater depth and in more detail, taking into account several 
factors as with a potential to influence outcomes following STEMI that have 
been highlighted in current literature, but were not included in the previous two 
studies.  
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CHAPTER 1 
Can Global Thrombosis Test predict thrombotic complications and 
major adverse cardiac events (MACE) in STEMI patients undergoing 
PPCI? 
 
Background 
Primary percutaneous coronary intervention (PPCI) is currently the preferred 
option for coronary revascularization in patients with time from symptom (chest 
pain and/or dyspnea) onset of less than 12 hours, with persistent acute ST-
segment elevation on electrocardiography (ECG) or with ST-segment elevation 
equivalents (Conference, Bcs, & Us, 2013). Coronary revascularization with 
PPCI, is also indicated in patients with time from symptom onset exceeding 12 
hours, in the presence of continuing ischaemia, life-threatening arrhythmias or 
if pain and ECG changes have been stuttering (Steg et al., 2012).  
Based on electrocardiographic criteria, acute STEMI, is defined as ST elevation 
>1mm in 2 or more contiguous limb leads or ST elevation >2mm in 2 or more 
chest leads. STEMI equivalents do not exhibit the classical ECG changes, but 
are associated with acute coronary occlusion and subsequently poorer 
outcomes and worse prognosis. The common STEMI equivalents are left main 
coronary occlusion with lead aVR ST-segment elevation, new or presumably 
new left bundle branch block (LBBB) and isolated posterior MI (Conference et 
al., 2013). 
Furthermore, the duration from the time of symptoms onset until coronary 
revascularization, is of vital importance, as occlusive thrombus composition 
changes, from an initial platelet abundance to a gradual replacement by fibrin, 
making PPCI technically more difficult in achieving a final TIMI III flow in the 
culprit coronary artery. Additionally, prolonged coronary occlusion leading to 
extended myocardial necrosis, predisposes to unwanted life-threatening 
clinical complications, such as heart failure with cardiogenic shock, arrhythmias 
and death (Blankenship et al., 2011). 
 
 
The choice of stent type during PPCI is of extreme importance. There are 
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currently two types of stents, the drug-eluding stent (DES) and the bare-metal 
stent (BMS). The former has three components, the metallic stent platform, the 
polymer coating and the anti-proliferative agent (Stefanini & Holmes, 2013). 
Available stent platforms are made of cobalt-chrome, platinum-chrome or 
stainless steel. Cobalt-chrome, as well as platinum-chrome alloys, provide 
good radial strength and increased radio-opacity, allowing for engineering of 
thinner struts that enable better stent delivery. Thinner struts in stent platforms, 
reduce the risk of coronary injury and consequently the risk of stent thrombosis 
(Stefanini & Holmes, 2013). The polymer coating acts as a drug carrier and 
allows controlled release of the drug (Stefanini & Holmes, 2013) . 
Anti-proliferative agents are highly lipophilic molecules that are distributed into 
the coronary wall, exerting either immunosuppressive effects (inhibitors of 
mammalian target of rapamycin) or anti-proliferative effects (paclitaxel) on 
smooth-muscle cells (Stefanini & Holmes, 2013).                                             In 
clinical practice, new generation stents releasing everolimus and zotarolimus 
and consisting of either cobalt-chrome or platinum-chrome platforms with 
thinner struts, have almost completely replaced paclitaxel-eluding stents and 
sirolimus-eluding stents, with the latter stopped being manufactured (Stefanini 
& Holmes, 2013).  Drug-eluding stents allow physiological arterial healing with 
smooth endothelial coverage of all stent struts, but they prevent neo-intimal 
hyperplasia. Excessive anti-proliferative effects can lead to chronic 
inflammation and increasing thrombogenicity. Sirolimus and paclitaxel-eluding 
stents were associated with delayed arterial healing, featuring incomplete 
endothelialisation of stent struts, vessel remodelling, increasing platelet and 
fibrin deposition, as well as premature atherosclerosis. Usage of new-
generation DES though, has resulted in better endothelial coverage, with 
consequent reduction in the occurrence of the above features (Stefanini & 
Holmes, 2013).  
Lately, the emergence of biodegradable polymers, aimed to offer the benefits 
of a conventional DES in the early phase and a BMS at later stages, by enabling 
both controlled drug release and polymer biodegradation initially, leaving only 
the stent platform eventually. Another type of new DES is the polymer-free 
 34 
DES, aiming to avoid potential adverse long-term effects of polymer presence. 
These two stent types are promising and currently being tested in clinical trials 
(Stefanini & Holmes, 2013). 
In recent years, a third generation bioabsorbable drug-eluding vascular scaffold 
(BVS) has been released, aiming to provide transient vessel support with drug 
delivery capability, that in theory will not exhibit the long-term disadvantages of 
metallic DES, such as permanent vessel caging, possible malapposition, late 
stent thrombosis, local inflammation and neo-atherosclerosis. Furthermore, 
BVS can restore vascular physiology and anatomical integrity, as they provide 
only a temporary scaffold needed to maintain the patency of the vessel 
undergoing angioplasty. At the moment, there are four types of BVS, based on 
the material used for their manufacture. Lactide polymers are present in several 
devices and they are the most extensively investigated. Other materials include 
magnesium, polyanhydrides and polycarbonates (Stefanini & Holmes, 2013) . 
Bare metal stents (BMS) were initially made of stainless steel, due to the fact 
that this material is biologically inert. Over the years though, cobalt-chromium 
and platinum-chromium alloys have replaced stainless steel as the material of 
choice for stents, due to their thinner struts that improve radial strength and 
enable corrosion resistance (Bangalore et al., 2013).  
Choosing between BMS and DES is not always an easy task, and indeed there 
are some variations among different operators, as well as between regional and 
international guidelines. In general, it is acceptable that shorter lesions 
(≤15mm) in bigger vessels (≥3mm in diameter) in non-diabetic patients can be 
treated with BMS. On the other hand, diabetic patients, patients with lesions 
≥15mm in length or patients with small diameter vessels (<3mm in diameter) 
should receive DES, provided that dual anti-platelet therapy (DAPT) is not 
contra-indicated. Also BMS should be inserted in patients not willing to receive 
DAPT or they have a medical condition in which prolonged DAPT is contra-
indicated. Diabetes mellitus has been identified as an independent predictor of 
in-stent restenosis (ISR), therefore it is of no surprise that diabetic patients 
receiving DES have significantly lower rates of acute MI, death and repeat 
revascularisation, compared to those treated with BMS. However, diabetic 
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patients with multi-vessel coronary disease should be referred for coronary 
artery by-pass graft (CABG) operation, based on recent evidence (Iqbal, Gunn, 
& Serruys, 2013). 
Data from 126 randomised trials (more than 250000 patient years of follow-up) 
has shown that biodegradable polymer DES are not superior to new generation 
durable polymer for both efficacy and safety outcomes. Also newer generation 
durable DES were the most effective stents as they exhibited the lowest rate of 
repeat revascularisation, no increase in very late stent thrombosis and 
significant decrease in the risk of MI. Additionally, a decrease in definite stent 
thrombosis, MI and death were observed when cobalt-chromium stents were 
compared with BMS (Bangalore et al., 2013). 
Selection of the appropriate anti-thrombotic regimen to accompany stent 
selection is the next task when managing STEMI patients undergoing PPCI. 
These regimens include a combination of anti-platelet agents and procedural 
anticoagulants, such as unfractionated heparin with glycoprotein IIb/IIIa 
inhibitor (GPI)(reopro) or bivalirudin (direct thrombin inhibitor). The 3-year 
report from the HORIZONS-AMI trial states that use of bivalirudin in STEMI 
patients undergoing PPCI, significantly reduces non-CABG-related bleeding, 
re-infarction and all cause mortality, when compared with treatment with 
unfractionated heparin and GPI. However, no difference was observed 
between groups in the rates of stent thrombosis, target vessel 
revascularisation, stroke and net adverse clinical events (Stone et al., 2011). 
Current guidance for secondary prevention for cardiovascular disease, 
suggests that a combination of two different anti-platelet agents should be 
administered for a period of twelve months, irrespective of the type of the stent 
implanted. Once patients complete this twelve-month dual anti-platelet agent 
course, one agent should be discontinued and they should continue taking the 
other one, which is usually aspirin, for life. The anti-platelet agent which is most 
commonly prescribed nowadays in combination with aspirin is ticagrelor, 
however very often clopidogrel is also prescribed in many cardiac centres (Roffi 
et al., 2015).  
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Once decision has been made about suitability of a patient for PPCI, immediate 
administration of a loading dose of Aspirin (300mg orally) and Copidogrel 
(600mg orally) or Ticagrelor (180mg orally) should follow, before initiation of the 
procedure. The purpose of this is to prevent further thrombus formation, that 
not only can establish total coronary occlusion, but it can also prolong the 
process of revascularisation during PPCI, leading to extended myocardial 
necrosis and consequently life threatening peri-procedural complications and 
long-term heart failure issues (Roffi et al., 2015). 
Following successful angioplasty, maintenance dose of aspirin (75mg daily) 
and clopidogrel (75mg daily) or ticargelor (90mg twice a day) is recommended, 
with the medical team emphasising the importance of drug compliance, in order 
to avoid stent thrombosis and further MI, which is expected upon premature 
discontinuation of dual anti-platelet treatment (Roffi et al., 2015). 
Based on the latest guidance, it is acceptable to discontinue the second anti-
platelet agent three to six months following DES implantation and one to three 
months following BMS or new generation DES implantation, in case of very 
high bleeding risk or need for non-cardiac surgical operation that cannot be 
postponed (Roffi et al., 2015). 
Identification of patients at high risk of major adverse cardiac events (MACE) 
post-PPCI has always been a major challenge, and currently no risk 
stratification model can be fully applied to these patients, due to lack of 
adequate number of subjects when some studies were carried out, as well as 
due to failure to include some very important parameters that determinate 
future outcomes post-PPCI, such as door-to-balloon time (DTB time), initial 
TIMI flow prior to mechanical revascularisation, type of anti-platelet agents and 
whether a loading dose has been used, level of left ventricular function 
impairment assessed by echocardiography (Mrdovic et al., 2013). 
MACE is the composite of end points, reflecting both the safety and 
effectiveness of various MI treatment approaches.  In literature, three 
definitions of MACE have been described, including a definition postulated to 
relate primarily to safety (death, MI, or stent thrombosis), and two definitions 
postulated to relate to both safety and effectiveness (death, MI, stent 
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thrombosis, or target vessel revascularisation and death, MI, stent thrombosis, 
or any repeat revascularisation) (Kip, Hollabaugh, Marroquin, & Williams, 
2008). Occurrence of adverse outcomes in STEMI patients is higher within the 
first 30 days after infarction and despite their low incidence, their potentially 
catastrophic consequences still create great concern (Mrdovic et al., 2013).  
Stent thrombosis, is a serious complication of treatment with both BMS and 
DES. According to the Academic Research Consortium, stent thrombosis has 
been given a definition based on the time of occurrence following angioplasty 
and the degree of diagnostic certainty. Early thrombosis occurs ≤1 month, late 
occurs between 1 month and ≤1 year and very late >1 year, and the degree of 
diagnostic certainty as definite, probable and possible (Stefanini & Holmes, 
2013). It is related to procedural factors, as well as to inadequate platelet 
inhibition during the early post-implantation period and chronic inflammation 
leading to delayed arterial healing. Furthermore, aspirin and/or clopidogrel 
resistance has recently emerged as another cause of stent thrombosis. Aspirin 
resistance, the incidence of which varies between 5-60% among patients with 
cardiovascular disease, has a multi-factorial aetiology (Casterella, n.d.). Non-
absorption, insufficient suppression of COX-1, over-suppression of COX-2 
mRNA, erythrocyte-induced platelet activation, GP IIb/IIIa receptor 
polymorphism, collagen receptor polymorphism, vWF receptor polymorphism, 
P2W1 single nucleotide polymorphism are the major potential factors leading 
to aspirin resistance, as described in literature (Casterella, n.d.). Clopidogrel 
resistance varies from 4-30% in patients with coronary artery disease (CAD), 
depending upon the clinical scenario, test assay, and clopidogrel dose 
prescribed (Casterella, n.d.). Several contributing factors leading to this 
complication have been identified and are divided into intrinsic and extrinsic. 
Extrinsic factors include drug interactions, CYP3A4 activity, variable pro-drug 
absorption, variable active metabolite clearance and intrinsic factors include 
P2Y12 receptor variability, increased intrinsic ADP levels and up-regulation of 
other platelet pathways (Casterella, n.d.).  
Several strategies have been suggested in order to tackle occurrence of anti-
platelet resistance. Firstly, there is need for standardised methods of platelet 
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function testing and interpretation, along with integration of point-of-service 
testing, that may assist in individualising anti-platelet therapy and subsequently 
to improve outcomes in patients with aspirin/clopidogrel  resistance. Usage of 
new agents with a more reliable pharmacologic effect and/or reduced incidence 
of resistance, may further assist in dealing with the unwanted effects of 
antiplatelet therapy resistance (Casterella, n.d.).  
Although many platelet function tests (PFT) are currently available, none of 
them has reliably predicted the risk of thrombosis yet and there are several 
reasons to explain this. Firstly, all currently used PFTs measure the response 
of platelets to specific agonists, even though in the pathogenesis of thrombosis, 
lots of factors, such as high shear stress and thrombin generation are 
implicated. Additionally, these tests do not assess the role of thrombin 
formation, which is now recognized as a key factor in the process of arterial 
thrombosis, as they are performed on citrate-anticoagulated blood that 
prevents the in-vitro assessment of thrombin generation by activated platelets. 
Furthermore, currently used PFTs do not assess spontaneous endogenous 
thrombolysis (ET), which is an important, yet under-investigated, component of 
defense against lasting arterial occlusion, as MI is the result of failure of timely 
spontaneous thrombolysis (Gorog & Fuster, 2013). The role of global 
thrombosis has never been mentioned in any of the current risk stratification 
models, and based on data from previous studies using the global thrombosis 
test (GTT), proving the role of impaired ET as a predictor of MACE in acute 
coronary syndrome (ACS) and end-stage renal impairment (Saraf et al., 2010) 
(Sharma et al., 2012), it is fair to conclude that the need of more advanced risk 
stratification models is necessary, in order for high risk patients to be accurately 
identified and treated accordingly. For example, identified patients with 
impaired endogenous thrombolysis could be treated more aggressively. 
Additionally, patients demonstrating enhanced thrombotic tendency, a possible 
sign of anti-platelet medication resistance, could be either treated with higher 
doses of anti-platelet agents or have one or both their anti-platelet agents 
switched to different ones. Also, in patients exhibiting delayed thrombotic 
and/or enhanced thrombolytic tendency, in whom bleeding risk is potentially 
higher, different strategies could be followed in prescribing anti-thrombotic 
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medication, in order to balance the risk of stent thrombosis against that of 
bleeding. 
 
Bleeding is a potential complication in STEMI patients, resulting due to patient’s 
bleeding diathesis, as well as secondary to anti-platelet agent use. It can occur 
at any time from the onset of STEMI management onwards and it could be life 
threatening in some occasions. For example, a major bleeding event on its own, 
is a life threatening situation to manage, but dealing with it in a very early stage 
post-PPCI with DES implantation, is an extremely challenging situation for the 
team managing the case, as any decision made regarding treatment can be 
proven to be a double-edge sward.  
The above statement highlights the great importance in usage of accurate 
bleeding risk stratification scoring systems when managing STEMI patients. 
The CRUSADE, ACUITY-HORIZONS, and ACTION risk scores demonstrated 
good calibration and discrimination for major bleeding prediction in STEMI 
patients undergoing PPCI, however the CRUSADE and ACTION risk models 
showed greater predictive capacity for major bleeding than the ACUITY-
HORIZONS risk score (Flores-Ríos et al., 2013). CRUSADE and ACTION 
models distinguished five risk categories of bleeding (very low, low, moderate, 
high, and very high risk) (Flores-Ríos et al., 2013). 
 
Aims 
This study is unique, because it aims to investigate for first time the role of 
global thrombosis test (GTT) in identifying STEMI patients undergoing PPCI, 
that remain at risk of thrombotic complications and MACE, despite being on 
dual anti-platelet therapy. Accurate identification of high risk patients will enable 
clinicians to adjust pharmacotherapy in such a way that the incidence of acute 
thrombosis can be significantly reduced. On the other hand, by assessing 
patients’ global thrombosis status, another complication such as bleeding can 
also be tackled. In this way, future management of patients with ischaemic heart 
disease (IHD) will be tailored to their needs, based on evidence from the GTT, 
aiming to reduce all possible complications to the minimum. 
 
Methods 
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Study design This was a prospective, observational, single-centre study, it 
was approved by the local research ethics committee and all subjects gave 
written informed consent in order to participate. 
Eligibility criteria Patients admitted to our unit with a presumed diagnosis of 
ST-elevation MI were included. Acute STEMI is defined as ST-elevation >1mm 
in 2 or more contiguous limb leads or ST-elevation >2mm in 2 or more chest 
leads. Common STEMI equivalents are left main coronary occlusion with lead 
aVR ST-segment elevation, new or presumably new left bundle branch block 
(LBBB) and isolated posterior MI (Conference et al., 2013), and were also 
included in our study. Exclusion criteria are listed in table 1: 
Table 1. Exclusion criteria 
Age below 18 years 
Refusal to provide informed consent 
Life expectancy of less than 1 year due to known non-cardiovascular condition 
Administration of thrombolytic agent or glycoprotein IIb/IIIa before PPCI 
Heparinisation of inserted arterial sheath or administration of intra-arterial heparin 
before obtaining initial GTT sample. 
Blood sampling Blood samples were taken at 4 time-points: 1) upon 
presentation, before PPCI, 2) after the administration of reopro, 3) prior to 
hospital discharge and 4) at 4-6 weeks follow-up. The choice of the timing of 
samples was made for the following reasons: The first sample reflects an 
individual’s global thrombosis status. We would not expect that aspirin and 
clopidogrel loading doses given within at most the previous 30 minutes to the 
patient, would have affected the GTT results much. With the second and third 
samples, we would like to investigate for possible changes in the global 
thrombosis status on and off reopro. With the last sample we aimed to 
investigate global thrombosis status once the patient is clinically stable and 
whether we can detect for possible antiplatelet resistance. The first samples 
were taken through the radial or femoral sheath. Before their insertion in the 
artery, sheathes were only flushed with normal saline, the first 15ml of arterial 
blood obtained following insertion were used for routine blood tests and the 
next 5ml sample was used for thrombotic status assessment. The second 
sample was again taken via the sheath, having discarded the first 5ml and used 
the next 5ml for thrombotic status assessment. The 3rd and 4th samples were 
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taken using a 16G butterfly cannula via an antecubital vein. Again the first 5ml 
was used for routine blood tests and the next 5ml used for thrombotic status 
assessment. 
PPCI protocol All patients had received loading doses of Aspirin (300mg) and 
Clopidogrel (600mg) in the ambulance or the emergency department upon 
diagnosis of STEMI, either orally or via a nasogastric tube. The PPCI procedure 
was performed either via the radial or the femoral routes and according to 
conventional practice. At the time, it was standard protocol in our unit to use 
reopro for almost all cases where PPCI was undertaken. 
Assessment of thrombotic and thrombolytic status Thrombotic status and 
endogenous thrombolytic activity were assessed using the Global Thrombosis 
Test, GTT (Montrose Diagnostics Ltd., UK). This novel, point-of-care assay 
employs native blood to assess the time taken to create a shear-induced 
thrombus under physiological conditions (occlusion time OT; seconds) and in 
the second phase of the test, measures the time to achieve endogenous 
thrombolysis of the thrombus created during the first phase (lysis time, LT; 
seconds). If lysis does not occur until 6000 seconds following OT (LT cut-off 
time), “No lysis” is displayed and recorded. The coefficient of variation (cv) was 
assessed by testing 10 healthy volunteers twice, at 48-hour intervals. 
Study endpoints The primary end point of the study was occurrence of a major 
adverse cardiovascular event (MACE) at 1 year, defined as the composite of 
cardiovascular death, non-fatal MI or stroke. Secondary endpoints included 
major bleeding as defined by GUSTO/TIMI Classification, not related to index 
procedure or non-cardiovascular death. 
New cardiovascular events were diagnosed in the presence of (1) 
cardiovascular death, defined as death in the presence of ACS, significant 
arrhythmia, or refractory congestive heart failure or death attributed to 
cardiovascular cause at post-mortem; confirmed from death certificates as well 
as medical records and observers’ accounts. Sudden death was included as 
cardiovascular events, or (2) non-fatal MI, defined as a rise in serum Troponin 
I or Creatine Kinase-MB isoenzyme ≥x2 upper normal limit, with at least one of 
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the following: acute onset ≥20 minutes typical ischaemic chest pain; ST-
segment elevation ≥1mm or ST-segment depression ≥0.5mm in ≥2 contiguous 
leads; or T wave inversion >1mm in leads with predominant R waves. 
New-onset cerebrovascular event was suspected with recent onset of 
neurological symptoms or signs, e.g., aphasia, focal deficits, or unilateral 
paresis, thought to be vascular in origin and confirmed by computerised-
tomography or MRI. 
New onset major bleeding was defined based on TIMI and GUSTO bleeding 
classifications (see tables 2 and 3): 
 
Table 2. TIMI bleeding classification (Rao et al., 2006) 
 
TIMI Bleeding Classification   
Major 
Intracranial haemorrhage or a ≥5 g/dl decrease in the haemoglobin 
concentration or a ≥15% absolute decrease in the haematocrit 
Minor 
Observed blood loss: ≥3 g/dl decrease in the haemoglobin concentration or 
≥10% decrease in the haematocrit 
Requiring 
Medical 
Admission 
No observed blood loss: ≥4 g/dl decrease in the haemoglobin concentration 
or ≥12% decrease in the haematocrit 
Minimal 
Any clinically overt sign of haemorrhage (including imaging) that is 
associated with a <3 g/dl decrease in the haemoglobin concentration or <9% 
decrease in the haematocrit 
 
 
 
 
 
 
Table 3. GUSTO Bleeding classification (Rao et al., 2006) 
 
GUSTO Bleeding Classification  
Severe or 
life-
threatening 
Either intracranial haemorrhage or bleeding that causes haemodynamic 
compromise and requires intervention 
Moderate 
Bleeding that requires blood transfusion, but does not result in 
haemodynamic compromise 
Mild Bleeding that does not meet criteria for either severe or moderate bleeding 
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Data collection and follow-up Basic demographics were obtained during 
index admission from patients’ medical notes and if necessary from their 
primary care records. Follow-up was done either in person, or over the 
telephone at 1, 3, 6 and 12 months. Collection and adjudication of events was 
performed blinded to GTT results. Source documents for all adverse events 
were obtained. 
Statistical analysis Analysis was performed with Stata/IC version 11.2. Paired 
and unpaired t-tests were used for comparison of normally distributed variables 
and Mann-Whitney U-test was used for non-normally distributed variables. Chi-
squared test with continuity correction or Fisher’s exact test were used to 
compare dichotomous variables. With Univariate linear regression model we 
assessed the relationship between a continuous variable (dependent) given a 
dichotomised variable (independent). Spearman’s rank test was used for 
correlations’ analysis and (ROC) curve analysis for discrimination between 
patients with and without MACE. In order to compare survival curves we used 
Kaplan-Meier survival methods with log-rank tests. For investigation of the 
relationship between increasing LT and MACE we performed Univariate Cox 
proportional hazard regression on LT divided into bands of 1000s. In order to 
adjust for potential confounders that are associated with clinical end-points on 
univariate analysis, we used Multivariate hazard regression Cox model. Finally, 
for assessment of the added predictive ability of LT≥3000 for MACE, we used 
Net reclassification improvement (NRI). 
Baseline OT/LT were separately related to OT/LT at other pre-specified time 
points and OT/LT at the 4 pre-specified time points were separately related to 
study end-points, in order to establish whether any of the time points can be 
predictive of MACE or major bleeding. 
 
Results 
Table 4. Baseline patient characteristics 
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 Overall 
group 
(n=82) 
Baseline 
LT<3000s 
(n=71) 
Baseline LT 
LT≥3000s 
(n=11) 
P value 
Age, years 63±12 63±12 64±10 0.444 
Male 67(81.7) 61(85.9) 6(54.5) 0.025 
Diabetes 
mellitus 
13(15.9) 12(16.9) 1(9.1) 1.000 
Active 
smoker 
31(37.8) 29(40.8) 2(18.2) 0.193 
Hypertension 39(47.6) 33(46.5) 6(54.5) 0.749 
Prior CAD 12(14.6) 10(14.1) 2(18.2) 0.660 
Renal 
insufficiency 
4(4.9) 2(2.8) 2(18.2) 0.085 
PVD 2(2.4) 2(2.8) 0 1.000 
Prior CVA 1(1.2) 1(1.4) 0 1.000 
Prior aspirin 
use 
15(18.3) 12(16.9) 3(27.3) 0.414 
 
Table 5. Medications on discharge 
Medications 
on discharge 
Overall 
group 
(n=82) 
Baseline 
LT<3000s 
(n=71) 
Baseline LT 
LT≥3000s 
(n=11) 
P value 
Aspirin 80(97.6) 70(98.6) 10(90.9) 0.252 
Clopidogrel 79(96.3) 69(97.2) 10(90.9) 0.355 
VKA 4(4.9) 4(5.6) 0 1.000 
Beta-blocker 64(78.1) 56(78.9) 8(72.7) 0.699 
ACE inhibitor 68(82.9) 61(85.9) 7(63.6) 0.087 
Calcium 
agonists 
12(14.6) 9(12.7) 3(27.3) 0.199 
Statin 69(84.2) 61(85.9) 8(72.7) 0.369 
Nitrate 9(11.0) 8(11.3) 1(9.1) 1.000 
Insulin 5(6.1) 4(5.6) 1(9.1) 0.523 
Metformin 5(6.1) 5(7.0) 0 1.000 
For tables 4 and 5: Values are mean±standard deviation or n(%). Renal 
insufficiency is defined by creatinine levels>177μmol/L. Prior aspirin use was 
defined as use of the drug before hospitalisation. ACE: angiotensin-converting 
enzyme, CAD: coronary artery disease, CVA: cerebrovascular accident, PVD: 
peripheral vascular disease, VKA: vitamin K antagonist. 
Table 6. Blood tests on admission 
Biochemistry Overall 
group 
Baseline 
LT<3000s 
Baseline LT 
LT≥3000s 
P value 
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(n=82) (n=71) (n=11) 
Haemoglobin 
(g/L) 
139±20 140±19 130±27 0.115 
Haematocrit 
(%) 
42±6 42±6 39±6 0.077 
Platelet 
count 
(x109/L) 
257±71 253±70 286±72 0.154 
Creatinine 
(μmol/L) 
94±39 91±29 117±76 0.039 
C-reactive 
protein 
(mg/L) 
13±20 13±18 17±30 0.571 
Troponin I 
(ng/ml), peak 
at 12 hours 
20.2±27.7 21.3±28.5 9.8±16.7 0.336 
Total 
cholesterol 
(mmol/L) 
4.8±1.2 4.8±1.2 4.9±1.2 0.711 
Values are mean±standard deviation.  
Normal values: haemoglobin is 130-180 g/L in adult males and 115-165 g/L in 
adult females; haematocrit is 40-52% in adult males and 36-47% in adult 
females; platelet count is 150-400x109/L; creatinine is 60-110 μmol/L in adult 
males and 45-90 μmol/L in adult females; C-reactive protein is 0-5 mg/L; 
troponin I is <0.04 ng/ml; total cholesterol is ≤4.0mmol. 
 
 
 
 
 
 
 
 
 
Table 7. Angiographic, interventional and echocardiographic patient 
characteristics 
 Overall 
group 
(n=82) 
Baseline 
LT<3000s 
(n=71) 
Baseline LT 
LT≥3000s 
(n=11) 
P value 
1-vessel 
disease (VD) 
43(52.4) 39(54.9) 4(36.4) 0.260 
2VD 22(26.8) 17(23.9) 5(45.5) 0.141 
3VD 16(19.5) 14(19.7) 2(18.2) 0.902 
Culprit 
vessel 
    
LAD 25(30.9) 24(33.8) 1(9.1) 0.131 
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Diagonal 2(2.5) 2(2.8) 0 0.901 
LCA 9(11.1) 6(8.5) 3(27.3) 0.080 
OM 3(3.7) 3(4.2) 0 0.923 
RCA 42(51.9) 35(49.3) 7(63.6) 0.381 
GPI use 58(70.7) 52(73.2) 6(54.5) 0.285 
Bivalirudin 
use 
4(4.9) 3(4.2) 1(9.1) 0.444 
Balloon 
predilation 
57(69.5) 49(69.0) 8(72.7) 1.000 
Stent 
implantation 
    
BMS 19(24.4) 15(21.1) 4(36.4) 0.273 
DES 59(75.6) 52(73.2) 7(63.6) 0.514 
TIMI-3 flow     
Before PCI 14(17.5) 13(18.3) 1(9.1) 0.461 
After PCI 69(86.3) 59(83.1) 10(90.9) 0.520 
LV function 
after index 
event 
    
Normal 
(EF≥55%) 
45(59.2) 37(52.1) 8(72.7) 0.212 
Mildly 
impaired (EF 
45-54%) 
17(22.4) 16(22.5) 1(9.1) 0.333 
Moderately 
impaired (36-
44%) 
13(17.1) 13(18.3) 0 0.264 
Severely 
impaired 
(≤35%) 
1(1.3) 1(1.4) 0 0.673 
Values are mean±standard deviation or n (%). BMS: bare-metal stent, DES: 
drug-eluding stent, EF: ejection fraction, GPI: glycoprotein IIb/IIIa inhibitors, 
LAD: left anterior descending artery, LCA: left circumflex coronary artery, LT: 
lysis time, LV: left ventricle, OM: obtuse marginal artery, PCI: percutaneous 
coronary intervention, RCA: right coronary artery, TIMI: Thrombolysis in 
myocardial infarction. 
Table 8. Clinical outcome at 12 months of follow-up 
 Overall 
group 
(n=82) 
Baseline 
LT<3000s 
(n=71) 
Baseline 
LT 
LT≥3000s 
(n=11) 
HR (95% 
CI) 
P value 
Cardiovascular 
death, non-
fatal MI and 
stroke 
13(15.9) 9(12.7) 4(36.4) 3.31(1.02-
10.78) 
0.047 
Cardiovascular 
death 
8(9.8) 5(7.0) 3(27.3) 4.18(0.99-
17.51) 
0.051 
Non-fatal MI 3(3.7) 2(2.8) 1(9.1) 3.96(0.36- 0.263 
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43.94) 
Ischaemic 
stroke 
2(2.4) 2(2.8) 0 NA NA 
Major bleeding 2(2.4) 1(1.4) 1(9.1) 8.79(0.55-
140.46) 
0.124 
Values are n (%). 
CI: confidence interval, HR: hazard ratio, LT: lysis time, MI: myocardial 
infarction, NA: not available, cardiovascular death: death in the presence od 
acute coronary syndrome, significant arrhythmia or refractory congestive heart 
failure or death attributed to cardiovascular cause at post-mortem. 
 
We recruited 82 patients for this sub-study. Their clinical characteristics are 
demonstrated in tables 4-6, and their angiographic, procedural and 
echocardiographic characteristics are shown in table 7. Out of all variables 
interrogated for relation to baseline OT and LT, only smoking was found to be 
related to OT, as demonstrated by shorter (more thrombotic) OT in smokers 
compared to OT of non-smokers (294±105s vs. 365±153s, p=0.026). 
Furthermore, there was weak negative correlation between baseline OT and 
admission creatinine levels (r= -0.4, p=0.057) and weak positive correlation 
between baseline OT and pre-PPCI TIMI-3 flow (r= 0.2, p=0.063). On the other 
hand, baseline LT≥3000s was significantly associated with female sex, and 
admission creatinine levels. 
Univariate analysis suggested that the following clinical and interventional 
characteristics were related to MACE outcome: increasing age (p=0.008), statin 
therapy (p=0.012), prior aspirin use (p=0.001), beta blocker use (p=0.024), 
angiotensin-converting enzyme (ACE) inhibitor use (p=0.0008), calcium 
antagonist use (p=0.001), history of renal insufficiency (p=0.002), elevated 
admission serum creatinine (p=0.001) and culprit vessel being the right 
coronary artery (p=0.02). There was weak relation between bare metal stent 
insertion and MACE (p=0.077) and finally there was no relation between any of 
the variables and major bleeding outcome, however the number of events was 
small. 
Certain variables were entered into the final baseline multi-variate Cox 
proportional hazard model (age with HR: 1.07, 95%CI: 1.02-1.13, p=0.005, 
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statin therapy with HR: 6.39, 95% CI: 1.95-20.99, p=0.002, previous diabetes 
mellitus diagnosis with HR: 0.51, 95% CI: 0.15-1.71, p=0.276 and previous 
diagnosis of hypertension with HR: 0.51, 95% CI: 0.16-1.6, p=0.246), however 
none of these covariates was found to be correlated, either with LT or its 
dichotomised version. Once more, baseline LT≥3000s was shown to be 
strongly associated with MACE (Figure 6), after adjustment for the baseline risk 
factors (HR: 4.26, 95% CI: 1.13-16.01, p=0.032). Finally, net reclassification 
improvement (NRI) demonstrated that inclusion of baseline LT≥3000s in a 
model containing three baseline predictors, such as age, previous diagnosis of 
diabetes mellitus and statin use, significantly added to the model effectiveness 
(NRI estimate: 0.347, p=0.018). 
OT was normally distributed at baseline, however shortly after treatment with 
GPI (65% of patients received the medication), OT was markedly prolonged 
compared to baseline (743±157s vs. 330±136s, p=0.00001. OT remained 
significantly prolonged prior to hospital discharge (536±195s vs. 331±129s, 
p=0.00001) compared to baseline and there was change between hospital 
discharge and at 1 month follow-up (529±195s vs. 528±144, p=0.995) (Figures 
2 and 3). 
At baseline, LT was positively skewed and many patients exhibited prolonged 
lysis times. Following treatment with GPI, LT was significantly reduced 
compared to baseline LT (709±149s vs.140±210s, p=0.00001). No difference 
was observed in LT at hospital discharge (1523±224s vs. 1332±206s, p=0.365) 
or at 1 month compared to baseline LT (1132±173s vs. 1239±194s, p=0.354). 
Also, at 1 month, LT was significantly reduced compared to baseline LT 
(1238±162s vs. 1598±221s, p=0.034) (Figure 4). 
A total of 13 MACE events were documented in 13 different patients. In specific, 
we recorded 8 cardiovascular deaths, 3 non-fatal MI (1 due to acute stent 
thrombosis within 24 hours from insertion and 1 due to late thrombosis, 76 
hours following insertion), 2 ischaemic strokes not related to atrial fibrillation 
and 2 major bleeding events. No issues were reported regarding anti-platelet 
agent compliance in any of these patients. MACE outcome was found to be 
strongly related to platelet reactivity at presentation, manifested as shorter 
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baseline OT (more thrombotic) in patients with adverse events compared to 
baseline OT in patients without MACE (253±150s vs. 354±134s, p=0.017) and 
particularly in the occurrence of non-fatal MI (OT 135±45s vs. 346±137s, 
p=0.009) and ischaemic stroke (133±31s vs. 343±38s, p=0.036) (Figure 7). 
There was no difference in baseline OT between patients with major bleeding 
and those without bleeding (297±121s vs. 339±141s, p=0.682). OT at other 
pre-specified time points was not related to MACE or major bleeding (Figure 7). 
Despite demonstrating the relationship between short baseline OT and MACE 
occurrence, no threshold was found in baseline OT, as a discriminator of MACE 
risk, as per ROC curve analysis (Figure 8). On the other hand, LT significantly 
discriminated between patients with and without MACE, with an area under the 
curve of 0.59 (95% confidence interval (CI): 0.471-0.693, p<0.05. LT≥2901s, 
was identified as the cut-off point to predict MACE (sensitivity 31% and 
specificity 89%) (Figure 9). However, we rounded this to 3000s for clinical ease, 
aided by the fact that no LT readings between 2900 and 3000s could have been 
wrongly classified based on this rounding. 
Survival analysis did not demonstrate any relationship between OT and MACE 
(hazard ratio [HR]: 0.99, 95% CI:0.989-0.999) or major bleeding at any pre-
specified time point. However, MACE was found to be strongly related to 
baseline LT, particularly when LT was ≥3000s (HR: 3.31, 95% CI:1.02-10.78, 
p=0.045), driven predominantly by cardiovascular death (HR: 4.17, 95% CI: 
0.99-17.51, p=0.051) (Figure 5). Baseline LT was not associated with an 
increase in the risk of major bleeding, however the number of events was small. 
Furthermore, no relationship between LT and MACE or major bleeding was 
observed at other pre-specified points.  
 
Figure 1. Distribution of OT at the 4 pre-specified time points. 
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(C) (D) 
 
 
 
 
(A): baseline, before PPCI, (B): after administration of GPI, (C): prior hospital 
discharge, (D): 1 month follow-up. GPI: glycoprotein IIb/IIIa inhibitor, OT: 
occlusion time. There is a significant shift of OT towards higher values due to 
the strong antithrombotic effect of aspirin/clopidogrel and reopro, as shown in 
diagram B. As the anti-thrombotic effect of reopro gradually wears off upon its 
discontinuation, average OT is slightly displaced towards the left (diagram C) 
and finally in the 1-month appointment, average OT lies in a position between 
the average value at baseline and the average value while on reopro. 
 
 
 
 
 
 
Figure 2. Distribution of LT at the 4 pre-specified time points. 
(A) (B) 
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(A): baseline, before PPCI, (B): after administration of GPI, (C): prior hospital 
discharge, (D): 1 month follow-up. GPI: glycoprotein IIb/IIIa inhibitor, LT: lysis 
time. These diagrams demonstrate enhancement of ET by reopro, as evident 
by the lower LT values in diagram B. As the effects of reopro wear off upon 
discontinuation, LT values shift towards the right, as demonstrated in diagrams 
C and D. Absence of LT values above 2000s in diagram B, shows the strong 
enhancement of ET probably promoted by reopro. 
Figure 3. OT values (mean±SD) at 4 pre-specified time points. 
 
*p<0.05, GPI: glycoprotein IIb/IIIa inhibitor, OT: occlusion time. This diagram 
demonstrates the antithrombotic effect of dual anti-platelet regimen of aspirin 
and clopidogrel, if we compare average OT at baseline and 1-month post-
hospital discharge tests. Additionally, it shows the strong anti-thrombotic 
properties of reopro, that in combination with anti-platelet agents, causes a 
huge increase in the average value of OT. 
Figure 4. LT values (mean±SD) at 4 pre-specified time points. 
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*p<0.05, GPI: glycoprotein IIb/IIIa inhibitor, LT: lysis time. In this diagram we 
can first observe a sudden decrease in the average value of LT while on reopro. 
This could be explained by the enhancement of ET by reopro, causing LT 
reduction. Secondly, we can observe a significant increase in LT upon 
discontinuation, which shows that the pharmacological effect of reopro in 
enhancing ET is short-lasting and perhaps there is a rebound adverse effect on 
ET upon reopro upon discontinuation, which is not translated into any increase 
in event rate as per data analysis.  
 
 
Figure 5. Hazard ratios (HR) for cardiovascular death, non-fatal MI, and stroke 
by baseline LT 
 
 
†p=0.077, * p<0.05, 95% confidence interval (CI) in brackets, 
CVD: cardio-vascular death, LT: lysis time, MI: myocardial infarction. Hazard 
ratios for CVD, MI and stroke significantly increase for LT values equal to or 
higher than 3000s. 
 
 
 
 
 
 
 
 
 
Figure 6. MACE and major bleeding according to baseline LT. 
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(A) (B) 
    
 
*p<0.05, †p=0.051 
CVD: cardio-vascular death, CVA: cerebro-vascular accident, LT: lysis time, 
MACE: major adverse cardiac event, MI: myocardial infarction. In diagram A 
we can see that MACE and major bleed are related to high LT at baseline and 
in diagram B there is proof that LT≥3000s can predict adverse events. 
 
 
Figure 7. Differences in baseline OT between patients with and without MACE 
and major bleeding. 
 
* p<0.05, CVD: cardio-vascular death, CVA: cerebro-vascular accident, MACE: 
major adverse cardiac event, MI: myocardial infarction, OT: occlusion time. 
Patients with stroke and non-fatal MI had significantly lower baseline OT. 
 
 
 
Figure 8. ROC curve for occlusion time at baseline 
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According to this diagram, baseline OT is not a discriminator of MACE. 
 
Figure 9. ROC curve for lysis time at baseline. 
 
Figure 9, demonstrating that baseline LT is indeed a discriminator of MACE, 
with an optimal cut-off value of 2901s. 
 
 
Figure 10. Probability of event-free survival in STEMI patients based on 
baseline LT. 
 
Thrombolytic status was strongly predictive to MACE, with baseline LT≥3000s 
being associated with HR of 3.31. Solid line indicates LT<3000s and dotted line 
indicated LT≥3000s. 
 
 
Discussion 
 55 
Previous studies of global thrombosis have highlighted the role of impaired ET 
in predicting increased risk of adverse cardiovascular events in patients with 
ischaemic heart disease. Our study has proven this once more, and in particular 
that impaired ET is predictive of cardiovascular death within one year from 
PPCI. We also showed that cut-off point of LT that predicts MACE is a value 
equal or higher than 3000s, which coincides with the results of previous studies 
of global thrombosis. However, we have also proven that enhanced ET leading 
to spontaneous coronary reperfusion and featured by short LT, complete or 
partial ECG ST-segment resolution and TIMI-3 coronary flow prior to 
intervention, is predictive of good post-PPCI outcomes, as described more 
extensively in another chapter. Furthermore, enhanced thrombogenicity, in the 
form of short OT, was associated with recurrent adverse events, such as non-
fatal MI and ischaemic stroke. 
 
DAPT with aspirin and clopidogrel, a pharmacological regimen extensively 
used worldwide, including the UK, for the prevention of stent thrombosis, has 
no effect on endogenous thrombolysis. On the other hand, it causes a long-
term reduction in thrombogenicity, as demonstrated by prolongation of OT 
during the 1-month follow-up testing. 
 
Usage of GPI in the acute phase, results in both prolongation of OT and 
reduction in LT, however as the medication is only given once during the PPCI 
and its effect wears off with time, it is expected to observe OT to slightly shorten, 
because DAPT still offers some prolongation of OT, and LT to return to 
baseline, because DAPT does not cause any reduction in the LT. 
 
Another interesting finding was the association of baseline LT≥3000s and 
female sex in STEMI patients, and given the fact that a previous assessment 
of global thrombosis status in healthy volunteers did not show any difference in 
LT between males and females, it is interesting for further studies to investigate 
possible tendency for delayed ET in women with STEMI, thus increasing their 
mortality risk compared to male patients. 
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Despite the relationship between creatinine and LT≥3000s, there is no 
evidence in this study that this blood marker is related to future adverse events. 
According to the results of previous studies of GTT, delayed ET predicts future 
adverse events in patients with cardiovascular disease and end-stage renal 
failure. However, in this study, creatinine levels were very high given the degree 
of renal impairment, which is not the case in our study.  
Therefore, the validity of our finding regarding creatinine, is questionable. 
 
The main limitation of the study is the small sample size. Also, due to the fact 
that several clinically unwell patients, such as patients with cardiogenic shock, 
were excluded from the study, as they were not able to provide us with an 
informed consent, we missed a great opportunity to assess global thrombosis 
in patients at potentially high risk of MACE. Although when in hospital patients’ 
compliance with medication is documented on a daily basis, it is impossible to 
confirm this upon hospital discharge, therefore during the 1-month follow-up 
GTT, results may not necessarily reflect the actual effect of DAPT. Of course 
this issue should be alleviated statistically with a significantly greater number of 
recruited patients. 
 
There are several other factors, potentially able to affect GTT results. The 
timing of aspirin/clopidogrel loading dose administration before GTT sampling 
was never documented, therefore it is not possible to know whether this had 
any effect on either OT/LT at baseline. Also we are unsure whether flushing of 
the arterial sheath with saline had any effect on the GTT results. Furthermore, 
in the absence of previous results of global thrombosis comparing samples 
from different vascular sites (arterial and venous), it is not possible to know 
about possible impact of this on the GTT results. In this study, with the 
exception of the baseline samples and in some occasions of the second sample 
(while on reopro), all the remaining samples were venous. Additionally, as 
variations in platelet reactivity between radial and femoral arterial blood has 
never been tested before, it is possible that not using the same arterial access 
for every study patient undergoing PPCI, may have affected GTT results as 
well. Finally, blood sample handling can affect the quality of the test, however 
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in this study there is not such an issue, as the majority of blood sample handling 
was performed by one operator. 
 
More studies are necessary to be carried out in order to investigate for more 
pharmacological agents exhibiting significant effects on global thrombosis 
status, thus serving their purpose of secondary prevention of coronary 
thrombotic events. The role of PAR-1 inhibitor vorapaxar in enhancing 
endogenous thrombolysis will be discussed in another chapter, however there 
are plenty of other anti-thrombotic agents currently tested in patients with 
ischaemic heart disease, such as the novel oral anticoagulants. Finally, the 
GTT which has provided us with consistent results in several studies of global 
thrombosis, could also be used for risk stratification purposes, in order to target 
high risk patients, in whom more aggressive pharmacological treatment would 
be necessary and conversely to prevent us from administering unnecessary 
anticoagulation to low risk patients. 
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CHAPTER 2 
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Investigation of the relationship between ST-segment resolution and 
global thrombosis 
 
Background 
According to the European Society of Cardiology/ACCF/AHA/ 
World Heart Federation Task Force for the Universal Definition of Myocardial 
Infarction, diagnostic ST-segment elevation, is defined as new ST elevation at 
the J point in at least 2 contiguous leads of 2 mm (0.2 mV) in men or 1.5 mm 
(0.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1mV) in other contiguous 
chest leads or the limb leads, in the absence of left ventricular hypertrophy or 
Left bundle branch block (LBBB) (O’Gara et al., 2013). 
The diagnosis of acute myocardial infarction requiring PPCI is made upon 
detection of acute onset of symptoms such as chest pain, dyspnea, dizziness, 
sweating, in the presence of either new ST-segment elevation as described 
above or new LBBB documented on electrocardiogram (O’Gara et al., 2013). 
In the majority of cases ECGs are performed by paramedics out of hospital, 
who are adequately trained to activate the PPCI pathway once STEMI criteria 
are fulfilled. After successful coronary revascularization (or historically, 
thrombolysis) there is resolution of ST segment elevation and normalization of 
the ST segments.  
The importance of ST-segment resolution (STR) following coronary reperfusion 
with either thrombolysis or PPCI has been highlighted in several articles and 
the role of ST-monitoring in STEMI patients has been found to be very important 
for very early risk stratification in these patients (Johanson et al., 2003). 
Furthermore, the extent of STR has been linked to the size of infarct, as well as 
to the risk of early mortality. In specific, it was found that complete STR was 
associated with small infarcts and low early mortality rates, whereas no STR 
was associated with large infarcts and high early mortality rates. Partial STR 
was associated with large infarcts, but low early mortality rates (R Schröder, 
Wegscheider, Schröder, Dissmann, & Meyer-Sabellek, 1995). 
 
In 2004, Rolf Schroder published a paper about prognosis in STEMI, based on 
the extent of early STR. According to this paper, there are three different ways 
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in assessing STR. The first method, sum STR, refers to resolution of the sum 
of ST-segment elevation, following reperfusion with thrombolysis or PPCI, and 
is used to predict infarct size, left ventricular function, epicardial vessel patency 
and mortality. Sum STR is calculated by measuring all ST-segment elevations 
in leads relevant to the infarct location. It is expressed as the percentage from 
baseline (Rolf Schröder, 2004).  
The second method is the Single-lead STR, which is measured by identifying 
the ECG lead with the most prominent ST-segment deviation between baseline 
and a given point of time following coronary reperfusion (Rolf Schröder, 2004). 
The final method of measuring STR is Max STE, which is the existing ST-
segment deviation at a given time and it is measured as per Single-lead STR, 
but it is not compared with baseline ST-segment deviation (Rolf Schröder, 
2004). According to the same paper, in order to define mortality risk groups, 
STR was categorised according to the extend of ST-resolution, namely as 
complete (>70%), partial (30-70%) and no resolution (<30%) (Rolf Schröder, 
2004). In single-lead STR, the cutoff for complete STR was defined as 
resolution of >70% for both anterior and inferior STEMI, whereas no resolution 
was defined as resolution of <50% in anterior STEMIs and <20% in inferior 
STEMIs. The following table illustrates the relationship between 30-day 
mortality rates against STR groups, with ECG recorded 90 minutes in 2719 
patients of the InTIME II Study (Rolf Schröder, 2004): 
 
 
 
 
 
 
 
 
 
 
Figure 1. 30-day mortality vs STR groups (Rolf Schröder, 2004) 
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In literature, there is some evidence that STR can also occur spontaneously, 
which is usually associated with good future outcomes (Search et al. 
2016)(Bainey et al. 2008). Even though it is believed that this phenomenon 
occurs due to spontaneous recanalization of an acutely occluded coronary 
artery, it is still unclear what the exact mechanism is. 
 
Aims 
We aimed to assess the relationship between global thrombosis status and 
spontaneous ST-segment resolution. Our hypothesis was that patients with 
spontaneous STR may have more effective endogenous thrombolytic 
pathways, enabling coronary thrombus lysis, with subsequent coronary 
reperfusion and STR. In addition to that, we also aimed to show that there is an 
association between spontaneous STR and low early mortality rates following 
STEMI. 
 
Methods 
For patients with evidence of STR, we compared the ECG on arrival at our unit 
with the ambulance ECG or the one done earlier in the A+E department. We 
then correlated this with OT and LT and angiographic findings. 
Of the five cases with spontaneous ST-segment resolution, only four were 
found to be suitable for PPCI, because one of them was an elderly patient with 
terminal cancer, who was completely asymptomatic on arrival at the cath lab, 
with completely resolved electrocardiographic changes and not wishing to have 
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an invasive procedure. The remaining four patients underwent coronary 
angiography. TIMI flow was assessed during coronary angiography using TIMI 
flow classification, as illustrated in Table 1: 
 
Table 1. Definition of TIMI flow (D a Morrow et al., 2000) 
 
TIMI Grade Description 
TIMI 0- no perfusion No anterograde flow beyond the 
point of occlusion 
TIMI 1- penetration without perfusion Faint anterograde coronary flow 
beyond the occlusion, with 
incomplete filling of the distal 
coronary bed 
TIMI 2- partial perfusion Delayed or sluggish anterograde 
flow with complete filling of the distal 
territory 
TIMI 3- complete perfusion Normal flow with complete filling of 
the distal territory 
 
 
In order to assess ST-segment resolution we used the Sum STR method, 
measuring all ST-segment elevations in leads relevant to the infarct location. 
We elected to choose this method, as we felt that it would be more accurate to 
diagnose ST-segment resolution by taking into account ST-segment changes 
occurring in more than one leads.  
 
Results 
Overall we had five patients with ST-segment resolution upon arrival at our 
cardiac centre, all of them associated with either complete or partial clinical 
symptom resolution. However, the most interesting finding was the short LT 
(<1000s), observed in all five cases. 
 
In patients with spontaneous ST-segment resolution, OT was no different to 
patients without spontaneous coronary reperfusion (306+/-156s vs 340+/-140s, 
p=0.609). Lysis time was inversely correlated with spontaneous coronary 
reperfusion before PPCI (r=-0.3, p=0.022). 
 
The following four images illustrate ST-segment elevation seen initially in two 
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of our study patients with STEMI, followed by spontaneous resolution of 
electrocardiographic changes on both occasions: 
 
Figure 2. Ambulance ECG (patient 1) 
 
 
 
 
 
 
Figure 3. Pre-PPCI ECG in the cath lab, 34 minutes after initial ambulance 
ECG (patient 1). 
 
 
 
 
Figure 4. Ambulance ECG (patient 2) 
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Figure 5. Pre-PPCI ECG in the cath lab, 65 minutes after initial ambulance 
ECG (patient 2). 
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Three out of four of our study patients with spontaneous STR, had TIMI 3 flow 
in their culprit vessel and one of them had TIMI 0 flow in the culprit vessel at 
angiography, before any coronary intervention. In comparison, in the patients 
from the PPCI group (discussed in chapter 1) without spontaneous STR, 14% 
had TIMI 3 flow, 4% had TIMI 2 flow, 11% had TIMI 1 flow and 70% had TIMI 
0 flow at presentation. 
 
Out of these four patients, one had unobstructed coronaries and did not require 
intervention. The remaining three patients had successful PPCI of their culprit 
vessel with DES. 
 
All five patients had uncomplicated hospitalization and had no events during 
the 1-year follow-up of our protocol. 
There was a total of 28 other patients who had LT<1000s, but without 
spontaneous ST-segment resolution and of these patients, 14% had TIMI 3 
flow, 0% had TIMI 2 flow, 14% had TIMI 1 flow and 71% had TIMI 0 flow at 
presentation. 
 
Discussion 
Three out of four patients had TIMI 3 flow at presentation, probably due to 
spontaneous coronary reperfusion, however this could well be coincidental due 
to the very small number of patients demonstrating STR. Based on the history 
and ECG changes, they clearly had transient coronary occlusion, which had 
resolved by the time of arrival and angiography. Although coronary spasm 
could be a possible explanation, acute coronary thrombosis is a more likely 
cause of the initial ST-segment elevations.  
All five patients had prolonged OT. This reflects reduced platelet activation. 
This in combination with the short LT, reflecting enhanced endogenous 
thrombolysis (ET) observed in the same patients, may be the reason for 
spontaneous coronary reperfusion and subsequently ST-segment/symptom 
resolution. Previous studies have shown no relationship between OT and major 
adverse cardiac event (MACE), even in cases of short OT (<200s). 
Furthermore, there has been no previous association between prolonged 
LT/short OT and MACE either. However, previous studies of ET (Saraf et al., 
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2010) (Sharma et al., 2012) did not investigate clinically unstable patients with 
potentially life threatening acute arterial thrombosis, but they concentrated on 
stable patients with angina and NSTEMI, in whom extremes of OT/LT may have 
not been clinically significant. Perhaps future GTT studies in PPCI patients 
should investigate whether a combination of short LT/prolonged OT at baseline 
significantly enhances thrombus lysis, leading to spontaneous coronary 
reperfusion with TIMI 3 flow and subsequent STR on these patients ECGs. 
 
In the acute setting, the role of enhanced ET in STR should not directly 
influence management, as there is no guarantee that TIMI III flow can be 
established, according to our study results. Furthermore there is data from 
other studies, also suggesting that angiography with a view to proceeding to 
PPCI should be immediately undertaken in STEMI without any delay, even if 
symptoms as well as ST-segment elevation have completely resolved (Sim, 
2015). Therefore, we do not suggest in any way that angiography and PPCI 
should be delayed or avoided in case of spontaneous STR related to enhanced 
ET (this paragraph also answers examiner’s comment regarding limitation of 
using STR as surrogate for TIMI 3 flow). 
 
 
The main limitation of this sub-study is the very small number of patients with 
spontaneous STR, therefore there is still no clear explanation about this 
phenomenon. Global thrombosis status may indeed contribute, however other 
parameters not considered in this study, may also favor STR. 
For example, the role of coronary collateralization has been recently suggested 
as a possible contributing factor to STR, in a study of 389 STEMI patients (Shen 
et al., n.d.). The majority of these patients had previous angina and hence CAD, 
leading to collateral vessel formation to support perfusion to the culprit vessel 
territory. 
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CHAPTER 3 
Does delayed ET increase the chance of peri-procedural complications 
in PPCI patients with prolonged door-to-balloon time (DTB)? 
  
In early ST-elevation MI (STEMI), the formation of occlusive thrombus composed 
of platelets and fibrin is a fast evolving process. Specifically, there is a dramatic 
change in the percentage of these two main constituents, from an initial 
significantly higher percentage of platelet compared to fibrin, to a later lowering of 
platelet content and simultaneous abundance in fibrin, making the thrombus more 
difficult to dissolve (Blankenship et al., 2011). This process is powerful enough to 
determine the outcome following STEMI, and the effectiveness of treatment with 
coronary revascularisation with primary percutaneous coronary intervention 
(PPCI) and in some rare occasions nowadays with thrombolysis. In the year 2000, 
the National Service Framework for Coronary Heart disease, emphasised the 
importance of pre-hospital thrombolysis (PHT) and the standard set out at the time 
was that STEMI patients ought to have thrombolytic agent administered 
intravenously within 60 minutes of calling for professional help. Alternatively, 
thrombolysis could be given soon after admission to the accident and emergency 
department (De Belder et al., 2008). In 2002 some cardiac units in the UK set up 
a PPCI service and since then this has developed to an extent, that it has now 
completely replaced PHT, since data from several studies worldwide has shown 
superiority of PPCI over thrombolysis. Firstly, PPCI is associated with reduced 
mortality and improved long-term outcome compared to thrombolysis, even when 
both are undertaken within a similar timeframe. Secondly, PPCI is associated with 
a lower risk of bleeding, stroke and coronary thrombosis, than thrombolysis. 
Importantly, after thrombolysis, the atherosclerotic lesion that predisposed the 
patient to thrombosis, still persists and thus the risk of recurrent infarction 
continues. In contrast, PPCI alleviates the coronary stenosis, allowing normal flow 
and reducing markedly the risk of re-occlusion due to thrombosis. Also more 
patients are suitable for PPCI than they are for thrombolysis, as there is a list of 
several major contraindications for the latter: 
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Table 1. Major contraindications for thrombolysis in STEMI (De Belder et al., 
2008). 
Any previous history of haemorrhagic stroke 
History of stroke, dementia or central nervous system damage within 1 year 
Head trauma or brain surgery within 6 months 
Known intracranial neoplasm 
Suspected aortic dissection 
Internal bleeding within 6 weeks 
Active bleeding or known bleeding disorder 
Major surgery, trauma or bleeding within 6 weeks 
Traumatic cardiopulmonary resuscitation within 3 weeks 
 
Finally, PPCI enables patients to have early treatment of the culprit coronary 
lesion and hospital discharge within 2-3 days from hospital admission, which is 
beneficial for both the patient from a psychological point of view, as well as for 
the NHS from a financial point of view. Supporting data for call-to-balloon times 
(CTB) in relation to patient follow-up firstly showed that mortality at all periods 
was lower when CTB time was shorter. Additionally for the cohort of patients 
with CTB time less than an hour, there was no later mortality. Finally it was 
noticed that as CTB time exceeded 120 minutes, mortality was noticeably 
diverged (De Belder et al., 2008). 
 
 
Table 2. Demonstrating mortality related to CTB time (De Belder et al., 2008) 
 
CTB time 
(minutes) 
In-hospital 
mortality (%) 
30 days 
mortality (%) 
1 year mortality 
(%) 
60-120 2.7 2.9 5.1 
120-180 4.5 4.9 8.7 
>180 11.4 12.2 15.9 
 
 
According to the national guidance for the treatment of myocardial infarction, it 
is crucial for STEMI patients to undergo urgent PPCI, as randomised trials and 
registries have shown increasing mortality as times to treatment lengthen (De 
Belder et al., 2008). 
Cardiac centres in the UK ought to achieve CTB times within 120 minutes and 
DTB times within 90 minutes, irrespective of the time or the day and regardless 
of their geographical location. Furthermore their performance should be audited 
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on a yearly basis to confirm national standards are achieved (De Belder et al., 
2008). 
 
If a thrombus is formed in a coronary artery, the natural defenses of enzymes 
which are responsible for endogenous thrombolysis, in particular t-PA released 
from activated platelets, should help dissolve that thrombus. If this natural 
defense mechanism is either overwhelmed or inefficient, the thrombus will 
persist in blocking the vessel and will worsen the outcome in patients with 
STEMI, since the persisting and stable thrombus will continue impairing 
myocardial perfusion. Relatively higher percentage of fibrin content within the 
thrombus and delay in coronary revascularization, could lead to prolongation of 
myocardial ischaemia time, reducing chance of myocardial salvage, with 
consequently more myocardial loss through infarction, heart failure, higher risk 
of arrhythmias and death. Inability to establish good distal flow and myocardial 
reperfusion, could predispose to a higher incidence of peri-procedural 
complications such as bleeding, coronary dissection, acute renal failure due to 
higher dose of contrast administration, exposure to higher doses of radiation 
(rare occasions of burns have been reported) (Blankenship et al., 2011). 
 
Previous studies have investigated the relationship between DTB/CTB times 
and future outcomes in STEMI patients undergoing PPCI, however it is not 
known how time from onset of infarction or delay in treatment would be reflected 
in thrombotic status. Therefore, demonstrating that short DTB/CTB times, as 
well as short LT and/or prolonged OT favor good future outcomes and vice 
versa, would be an exciting finding, as it would be additional evidence 
supporting the great importance of ET in ischaemic heart disease (IHD). 
 
 
 
 
 
 
Aims 
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We aimed to assess the relationship between time from onset of infarction and 
onset of treatment and relate this to thrombotic status. 
 
 
Methods 
In order to investigate the role of endogenous thrombolysis in the clinical 
outcomes of STEMI patients, in combination with the timing of PPCI, we 
documented PTB time, CTB time and DTB time for all patients participating in 
our study. 
 
Call-to-balloon time refers to the time between the call for ambulance help or 
medical assistance until balloon dilation (or other device use, such as thrombus 
aspiration device) achieving coronary reperfusion, and it is measured in 
minutes (De Belder et al., 2008). 
 
Door-to-balloon time is the time elapsing from arrival to the cardiac centre until 
balloon dilation (or other device use, such as thrombus aspiration device) 
achieving coronary reperfusion, and it is measured in minutes (De Belder et al., 
2008). 
 
Pain-to-balloon time (PTB time) is the time from the onset of symptoms until 
balloon dilation (or other device use, such as thrombus aspiration device) 
achieving coronary reperfusion, and it is measured in minutes.  
We assessed the relationship between thrombotic status (OT and LT) and CTB, 
DTB and PTB times using the following statistical methods. We also assessed 
the relationship between these times and outcomes (major adverse events). 
 
Results 
The total number of our PPCI patients was 82, with 71 of them having LT≤3000s 
and 11 of them LT>3000s. Neither DTB nor CTB times were related to lysis 
times. DTB was not related to MACE, even in the group with prolonged LT.  
Table 3. Comparing DTB and CTB times against LT  
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 Overall 
Group 
(n=82) 
Baseline 
LT  
<3000s 
(n=71) 
Baseline 
LT  
≥3000s 
(n=11) 
p 
Value 
Door to balloon time, min 24±16 23±16 26±14 0.519 
Call to balloon time, min 100±18 100±19 98±14 0.940 
 
 
We then investigated the influence of CTB time on events. Again there was no 
relationship between CTB time and events in any of the two LT groups. 
DTB and CTB times were not predictors of MACE in any OT group either, and 
there are several reasons to explain this. Firstly, due to the very short DTB and 
CTB times which reflect prompt coronary revascularisation, it was expected to 
observe very few complications/events, as previously discussed.  
As CTB time does not always reflect the time from the onset of STEMI 
symptoms and because we observed a consistent delay in calling for 
professional help in several of our study patients, we introduced the parameter 
of PTB time.  
 
Discussion 
DTB was not related to MACE, even in the group with prolonged LT. This could 
be explained primarily by the fact that DTB time seen in every single case was 
much shorter than the target suggested in the paper mentioned earlier, as well 
as by the small number of subjects included in the study. It could also be 
explained by the fact that patients with widely varying durations of infarction 
(PTB, CTB), could have similar DTB times. 
Therefore in our study with mean DTB time 23+/-16 minutes in the short LT 
group and 26+/-14 minutes in the prolonged LT group, it would be highly 
unlikely to observe statistically significant events. 
The lack of relationship between CTB time and LT could in part be explained 
by the short CTB times seen in both groups (100+/-19 minutes and 98+/-14 
minutes). Furthermore the small sample size is another reason for not 
observing a relationship with MACE, even in the prolonged LT group. 
It is possible that some patients are markedly pro-thrombotic and refractory to 
endogenous lysis, and that this prolonged lysis time measured in our study, is 
not related to time from onset of pain/infarction. Although we would have 
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expected that as the time from infarction (and before PPCI) lengthens the fibrin 
content of the thrombus increases and this would be reflected in more 
prolonged lysis time, it is possible that the small sample size was responsible 
for the fact that we were not able to measure this. 
Despite the fact that short DTB is required in order to reduce the risk of peri-
procedural complications in PPCI as previously explained, PTB is far more 
important, as it measures the time from the onset of the coronary event until 
time of re-perfusion with balloon. Unfortunately, this cannot always be accurate, 
because we entirely rely on patient’s memory of the event. Therefore, collateral 
history from patient’s friends or relatives present during the onset of the 
symptoms is essential for obtaining a more precise documentation of the onset 
of symptoms. 
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CHAPTER 4 
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Can Global thrombosis status predict future outcomes in patients 
undergoing elective or urgent PCI? 
 
Background 
Ischaemic heart disease (IHD) is the leading cause of death in the US and the 
UK, with one coronary event occurring every 25 seconds, from which 34% dying 
within the same year, that is one death every minute (Kones, 2011). 
Furthermore, it is estimated that every year there are 6.2 million hospitalisations 
in the US for cardiovascular disease (CVD) and 7.2 million cardiac and vascular 
procedures are performed, consuming 17% of the national health budget 
(Kones, 2011). Although the death rate related to IHD has fallen over the last 
years due to prevention and treatment strategies being implemented, the 
prevalence of risk factors, such as obesity and diabetes has reached alarming 
levels, not favoring further improvement in related morbidity and mortality. 
Therefore, more efforts should be made for lowering the prevalence of risk 
factors, in order to achieve lower cardiovascular related mortality rates (Kones, 
2011). 
Risk factors are divided into modifiable and non-modifiable. Non-modifiable 
factors include age, gender and genetics. Modifiable factors comprise smoking, 
diabetes, hypertension, obesity and dyslipidemia. There is also emerging 
evidence, emphasizing the importance of novel risk factors of IHD, such as C-
reactive protein (CRP), triglycerides, dense LDL, lipoprotein-associated 
phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6) and others. Complex 
interactions between genetic and environmental factors, influence the process 
of atherosclerosis throughout life, determining the likelihood of adverse 
coronary events (Kones, 2011). 
Primary prevention of CVD in patients with risk factors present, refers to 
preventing or delaying a first coronary event in these patients. This can be 
achieved with lifestyle changes, with or without administration of 
pharmacotherapy. However, in patients with diagnosed significant CAD, in 
whom the risk of adverse coronary event is high, treatment with primary 
percutaneous intervention (PCI) and additional pharmacotherapy is indicated, 
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in the form of statins for hypercholesterolemia, ACE inhibitors for hypertension 
and dual antiplatelet therapy for stent protection (Kones, 2011). 
Secondary prevention, seeks to prevent or limit recurrence of ischaemic 
coronary events (Kones, 2011). 
Between the two, the role of Primary prevention is far more important, yet more 
complex for implementation, because despite great efforts from different 
authorities in educating people regarding this issue, it is difficult to interfere and 
change social and cultural phenomena that prevent people from adopting 
healthy lifestyles. For example, coping with stress, smoking and dietary habits 
are not easy to be tackled in western societies, therefore the role of educating 
citizens about lifestyle modifications, should be undertaken by even more 
authorities, that should also try to discover different and more efficient 
strategies, in order to positively influence people. For instance, the role of 
educating public regarding non-healthy dietary habits, a major cause of obesity 
and subsequently diabetes and CVD, should be undertaken by even more 
authorities, such as education authorities (schools, universities), government 
departments and agencies, local authorities, NHS organisations, prison 
services and the armed forces. 
 
The role of NHS primary care is very important, particularly with regards to 
primary prevention. General practitioners are responsible for identifying 
patients at risk of developing CVD and for taking appropriate measures, 
according to primary prevention strategies, as set out by the National institute 
of clinical excellence (NICE). The role of secondary care (hospital doctors), 
which is the focus of this chapter, is to investigate high risk patients referred by 
primary care, for presence of CAD in one hand, and treat patients with 
diagnosed coronary events on the other hand. Investigations of patients 
suffering with possible angina, includes non-invasive imaging with a variety of 
modalities, such as myocardial perfusion scan, stress echocardiography, CT 
coronary angiography and cardiac MRI scans or invasive investigation, such as 
coronary angiography, which is the gold standard of investigations for detection 
of coronary artery disease (Kones, 2011). With the aid of coronary angiography, 
clinicians can diagnose CAD and its severity, enabling them to decide about 
mode of management for each patient. The first option is to treat patients 
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conservatively with pharmacotherapy, targeting modifiable risk factors, not 
optimally treated by general practitioners. In this occasion, pharmacotherapy 
for diabetes, hypertension, hypercholesterolemia can be either initiated or up-
titrated by clinicians. Furthermore, usage of anti-platelet agents in the form of 
aspirin is indicated, particularly in those with diagnosed CAD (Boon et al., 
2014). 
On the other hand, upon diagnosis of significant CAD, obstructing coronary flow 
and subsequently impairing myocardial perfusion, usage of pharmacotherapy, 
including agents previously mentioned, as well as anti-anginal agents (beta-
blockers, calcium channel blockers, nitrates and nicorandil), should be adjuvant 
therapy to PCI (Boon et al. 2014). Following PCI, patients should initiate dual 
anti-platelet therapy, usually with aspirin and clopidogrel, among others 
targeting risk factors. DAPT should continue for 12 months, at which point 
clopidogrel should be stopped and aspirin to continue being administered for 
life (Cheng, 2013). 
 
In a previous chapter we discussed the treatment in patients diagnosed with 
ST-elevation myocardial infarction (STEMI). In this chapter we will discuss the 
treatment of patients diagnosed with non ST-elevation MI (NSTEMI). A 
diagnosis of NSTEMI is accepted when, in the absence of ST-segment 
elevation, ischemic ST-segment or T-wave changes are present for at least 24 
hours with positive cardiac enzymes (troponin) or a typical clinical presentation, 
or both (McManus et al., 2011). It represents partial obstruction of one of the 
main coronary arteries or complete occlusion of one of the minor coronary 
arteries. In the absence of ischaemic ECG changes, a diagnosis of NSTEMI is 
also acceptable, in the presence of positive cardiac enzymes and relevant 
clinical presentation (McManus et al., 2011). Upon making diagnosis of 
NSTEMI, patients should be treated with a loading dose of aspirin and a second 
anti-platelet agent, such as clopidogrel, ticagrelor or prasugrel (Roffi et al. 
2015). Several trials have investigated the correct timing of coronary 
intervention (TIMACS/ABOARD/ISAR-COOL), with the general consensus 
being that this is better to be undertaken within 24 hours into hospitalization 
(Jneid et al., 2012). Following PCI, patients are advised to continue with DAPT 
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for 12 months and from then on with aspirin monotherapy for life (Roffi et al. 
2015). 
 
Despite introduction of new types of stents, improved stent insertion 
technologies and more effective anti-platelet regimens, stent thrombosis (ST) 
leading to MI is still possible, with estimated incidence between 1-5%. Based 
on the timing of its occurrence, ST can be classified as early when it occurs 
within 30 days from stent implantation, late when it occurs between 1 to 12 
months post-implantation and very late when it occurs after 12 months post-
implantation (Council & Vol, 2007). In a large Dutch study of 21,009 patients 
treated with either drug-eluding stent (DES) or bare-metal stent (BMS), it was 
shown that important determinants of this complication include anti-platelet 
non-compliance or early discontinuation, under-sizing of coronary stent during 
PCI, presence of moderate CAD proximal to the culprit lesion left untreated and 
co-existing malignant disease (van Werkum et al., 2009). Furthermore, the 
incidence of ST in patients undergoing elective PCI for angina, was lower than 
for those with ACS, undergoing urgent PCI and patients with STEMI undergoing 
PPCI demonstrated the highest incidence of ST. Also, STEMI patients 
experienced early ST more often than late or very late ST, compared to angina 
and ACS patients that demonstrated higher proportion of late and very late ST 
(van Werkum et al., 2009). In another paper, publishing the combined data from 
9 studies investigating predictors of ST, including 153,350 patients with 2495 
cases of ST, the commonest predictors of ST were the presence of diabetes 
mellitus, left ventricular dysfunction confirmed with echocardiography, ACS at 
admission, total stent number or stent length, anti-platelet therapy 
discontinuation before 30 days from stent implantation and extend of coronary 
disease (D’Ascenzo et al., 2013). However, even more risk factors are involved 
in the process of this catastrophic complication, that are listed in the following 
three tables: 
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Table 1. Procedure and lesion related parameters in relation to ST (Council & 
Vol, 2007). 
 
1. Use of multiple stents 
2. Small vessel diameter 
3. Coronary dissection 
4. Geographic miss 
5. Slow coronary flow 
6. Long coronary artery lesions 
7. Stent malapposition 
8. Stent underexpansion 
9. Stent design (type of polymer and strut thickness) 
10. Bifurcation lesions 
 
 
Table 2. Patient characteristics in relation to ST (Council & Vol, 2007). 
 
1. Diabetes mellitus 
2. ACS (especially STEMI) 
3. Left ventricular dysfunction (Heart failure) 
4. Renal impairment 
5. Advanced age 
6. Platelet reactivity 
 
 
Table 3. Antiplatelet therapy in relation to ST (Council & Vol, 2007). 
 
1. Non-compliance 
2. Premature discontinuation of antiplatelet therapy 
3. Inadequate intensity of therapy (insufficient dose or antiplatelet 
monotherapy, instead of dual therapy) 
 
 
High residual platelet reactivity (HRPR) or high on-treatment platelet reactivity 
(HTPR), which is one of the causes of ST, is defined as high platelet reactivity 
that is present within a few hours following loading dose of antiplatelet agents. 
According to literature, the risk of ischaemic events increases proportionally 
with higher values of platelet reactivity (Garabedian & Alam, 2013). However, 
there is still lack of an optimal method that could both accurately define HRPR 
and risk stratify patients.  
 
Several studies have been carried out in order to find appropriate strategies 
against HRPR and subsequently ischaemic event prevention. For example, in 
the GRAVITAS study, the aim was to identify the effect of high dose clopidogrel 
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versus standard dose clopidogrel on platelet reactivity. This was a multi-center, 
double-blind study, enrolling 2214 patients with HTPR, 12 to 24 hours post-PCI 
with DES for stable CAD or following NSTEMI. In this study the Verify Now 
assay was used in order to assess  platelet reactivity. Enrolled patients received 
high dose clopidogrel (loading dose of 600mg, followed by daily maintenance 
dose of 150mg/day) versus a placebo loading dose of clopidogrel, followed by 
maintenance dose of 75mg/day. Patients also received standard dose of aspirin 
on a daily basis. Furthermore, 586 patients without HTPR were also selected 
and followed-up throughout the study. Finally, all patients had two follow-up 
sessions (1 and 6 months from recruitment), with the VerifyNow assay being 
performed at each visit. The primary end-point for the study was the 6-month 
incidence of cardiovascular death, non-fatal MI and stent thrombosis 
(Garabedian & Alam, 2013). Despite the fact that this study did demonstrate 
significant reduction in platelet reactivity by using higher dose of clopidogrel, 
there was no evidence that this strategy reduces the primary end-point at 6 
month follow-up. The main limitation of this study was the small number of 
events observed and the exclusion of STEMI patients, that represent a higher 
risk population (Garabedian & Alam, 2013). 
Another study by Bonello et al, investigating platelet reactivity, aimed to show 
that tailored loading doses of clopidogrel could control residual platelet 
reactivity (Garabedian & Alam, 2013). This study confirmed a reduction in the 
rate of major adverse cardiac events and stent thrombosis in the short term, 
without increasing the risk of bleeding, however further studies need to be 
carried out in order to provide us with information regarding any long term 
benefits resulting from implementation of this strategy (Garabedian & Alam, 
2013). Therefore more and larger-scale studies should be carried out in order 
to further investigate platelet reactivity, by exploring for more accurate ways in 
measuring it and identifying patients at high risk of thrombotic and bleeding 
events. 
 
With enough evidence about the limitations of clopidogrel therapy due to 
platelet resistance, leading to recurrence of life-threatening ischaemic events, 
researchers moved their focus in developing new antiplatelet agents, aiming to 
achieve faster and more efficient platelet inhibition. In particular, ticagrelor, a 
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P2Y12 inhibitor that prevents ADP binding in order to prevent platelet 
aggregation, it has shown superiority compared to clopidogrel, when used in 
patients with stable CAD, as well as in patients with ACS, with or without ST-
elevation, undergoing PCI (Garabedian & Alam, 2013). Firstly it does not 
require metabolic activation for manifesting its effects. Secondly it has shown 
greater inhibitory effect on platelets following 180mg loading dose, when 
compared to a 600mg loading dose administration of clopidogrel. Finally it has 
been shown that this medication is metabolized faster than clopidogrel, with its 
inhibitory effects being weaned off faster than that of clopidogrel (Garabedian 
& Alam, 2013). In the NSTEMI sub-group of the PLATO trial (18,624 
participants), evaluating the efficacy and safety of ticagrelor against that of 
clopidogrel in NSTEMI patients, it was shown that usage of ticagrelor 
significantly reduces the rate of death related to vascular causes, MI or stroke, 
without increasing the overall risk of major bleeding. However, with ticagrelor 
therapy, higher rate of non-procedure related bleeding was observed (Lindholm 
et al., 2014). Additionally, in one of PLATO sub-studies, higher platelet 
reactivity was seen more frequently in the clopidogrel sub-group, following 
loading dose administration, as well as during maintenance dose, proving that 
greater platelet inhibition is achieved with ticagrelor (Garabedian & Alam, 
2013). 
Apart from searching for the best antiplatelet regimen following PCI, selection 
of an appropriate type of stent is also very important in reducing the risk of 
platelet resistance. New types of stents have been introduced in the market and 
more are still being tested, with a view to investigate for combinations of 
polymers and cytotoxic drug coatings that will affect vascular inflammation and 
tissue factor activity, which are determinants of thrombosis, as discussed in a 
previous chapter. For example stents with NO-donors could prevent platelet 
aggregation by decreasing platelet adhesion. Additionally, CD3 antibodies 
present in coatings, could prevent thrombosis by promoting stent 
endothelialisation via capturing circulating endothelial progenitor cells. Also, 
usage of biodegradable stents could reduce the incidence of late and very late 
stent thrombosis (Council & Vol, 2007). 
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Several platelet function tests (PFTs) have been used in clinical trials, however 
none of them has ever been very efficient in serving its purpose of accurately 
identifying patients at high risk of thrombosis or bleeding. Previously used PFTs 
have been designed to investigate platelet response to specific agonists, 
however thrombosis is a complex pathophysiological process, therefore other 
important determinants of thrombosis, such as shear stress and thrombin 
generation were not assessed at the time, thus failing to fully assess individual 
thrombosis status and its role in IHD (Gorog & Fuster, 2013). Apart from 
individual thrombosis status which has never been adequately investigated, the 
role of endogenous thrombolysis (ET) status had never been investigated either 
until recently, when published results from two studies showed consistent 
evidence that ET predicts future cardiac events in ACS and end-stage renal 
impairment patients respectively (Saraf et al., 2010) (Sharma et al., 2012). 
Assessment of both individual thrombosis and ET status (global thrombosis 
status) was performed using the global thrombosis test (GTT). Following 
discussion about the contribution of global thrombosis assessment in STEMI 
patients undergoing PPCI in a previous chapter, it would also be very important 
to investigate its role in patients with stable CAD and NSTEMI. 
 
Aims 
Primarily we aimed to demonstrate once more that ET predicts future adverse 
events following PCI, however we would also like to investigate which clinical 
or other patient characteristics influence individual ET status.  We also aimed 
to similarly investigate individual thrombotic status, with particular interest in the 
possibility of this predicting future adverse events following PCI, something that 
was not demonstrated on previous studies of global thrombosis. 
 
Methods 
Study design This was a prospective, observational, single-centre study, that 
was approved by the local research ethics committee and all subjects gave 
written informed consent in order to participate. For this sub-study we randomly 
recruited patients suitable for non-emergency PCI, following diagnosis of CAD 
by coronary angiography. They were either patients with angina symptoms, 
scheduled for an elective outpatient PCI or patients with confirmed diagnosis of 
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NSTEMI, scheduled for urgent inpatient PCI. Diagnosis of NSTEMI was made 
based on symptoms of coronary ischaemia, ECG changes (absence of 
changes does not exclude ACS) and rise in blood troponin (biochemical marker 
of myocardial damage). ECG changes include transient ST-segment elevation, 
persistent or transient ST-segment depression, T-wave inversion, flat T-waves 
or pseudo-normalization of T- waves (Roffi et al., 2015). 
 
Eligibility criteria All patients above the age of 18 years, with confirmed 
diagnosis of CAD and scheduled for PCI, able to provide us with written 
consent, were considered eligible for participation to our study. Patients with 
life expectancy of less than one year due to non-cardiac cause, patients with 
heparinised arterial sheath and patients administered intra-arterial heparin 
before obtaining initial GTT sample, were excluded for participation in the study. 
Blood sampling Blood samples were taken from a 16G butterfly cannula via 
an antecubital vein or through the radial/femoral sheath used for PCI. When the 
sheath was inserted, it was initially only flushed with normal saline, the first 
15ml of blood drawn were discarded, and the next 5ml sample was used for 
thrombotic status assessment.  
Medications All patients participating had already been loaded with 300mg 
aspirin and 300mg of clopidogrel and were scheduled to receive 75mg of aspirin 
daily for life and 75mg of clopidogrel daily for 12 months. Additionally, NSTEMI 
patients were administered daily subcutaneous injections of low-molecular 
weight heparin until PCI, as part of the ACS protocol (Roffi et al., 2015).                                                                                                  
Assessment of thrombotic and thrombolytic status Thrombotic status and 
endogenous thrombolytic activity were assessed using the Global Thrombosis 
Test, GTT (Montrose Diagnostics Ltd., UK). This novel, point-of-care assay 
employs native blood to assess the time taken to create a shear-induced 
thrombus under physiological conditions (occlusion time OT; seconds) and in 
the second phase of the test, measures the time to achieve endogenous 
thrombolysis of the thrombus created during the first phase (lysis time, LT; 
seconds). If lysis does not occur until 6000 seconds following OT (LT cut-off 
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time), “No lysis” is displayed and recorded. The coefficient of variation (cv) was 
assessed by testing 10 healthy volunteers twice, at 48-hour intervals. 
Study end-points The primary end point of the study was occurrence of a 
major adverse cardiovascular event (MACE) at 1 year, defined as the 
composite of cardiovascular death, non-fatal MI or stroke. Secondary end-
points included major bleeding as defined by GUSTO/TIMI Classification, not 
related to index procedure or non-cardiovascular death. 
Data collection and follow-up Basic demographics were obtained during 
index admission from patients’ medical notes and if necessary from their 
primary care records. Follow-up was done either in person, or over the 
telephone at 1, 3, 6 and 12 months. Collection and adjudication of events was 
performed blinded to GTT results. Source documents for all adverse events 
were obtained. 
Statistical analysis Analysis was performed using IBM SPSS statistics 
(version 23). Descriptive studies were used for calculation of standard deviation 
(SD) and means. Furthermore, we used this test to investigate the relationship 
between two linear values. Independent samples t-Test was used in order to 
investigate for statistically significant difference between unrelated groups and 
Crosstabs was used to describe the interaction between categorical values. 
ROC curve analysis was used to investigate for possibility of OT or LT to 
discriminate for events and Kaplan-Meier survival methods with log-rank tests 
to compare survival curves. 
 
 
 
 
Results 
Table 4. Baseline patient characteristics. 
 
Risk factor Yes/No LT<3000s(%) LT>3000s(%) Pearson Chi- P value 
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Square (df) 
Diabetes 
mellitus  
 
Yes 25 (19.2) 4 (18.2) 0.013 0.9 
  No 105 (80.8) 18 (81.8)   
Hypertension 
 
Yes 66 (51) 13 (59) 0.52 0.47 
 No 64 (49) 9 (41)   
Smoking 
 
Yes 29 (22.3) 2 (9.1) 2 0.155 
 No 101 (77.7) 20 (90.9)   
Prior CAD 
 
Yes 72 (55.4) 11 (50) 0.22 0.639 
  
No 
58 (44.6) 11 (50)   
Renal 
insufficiency 
 
Yes 12 (9.2) 2 (9.1) 0 0.983 
 No 118 (90.8) 20 (90.9)   
PVD 
 
Yes 2 (1.5) 1 (4.5) 0.879 0.348 
 No 128 (98.5) 21 (95.5)   
Previous CVA 
 
Yes 7 (5.4) 0 (0) 1.24 0.265 
 No 123 (94.6) 22 (100)   
Previous 
bleeding 
 
Yes 3 (2.3) 1 (4.5) 0.368 0.544 
 No 127 (97.7) 21 (95.5)   
 
Significance was taken as p<0.05, CAD: coronary artery disease, CVA: 
cerebrovascular accident, PVD: peripheral vascular disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Medications on blood sampling. 
Medication Yes/No LT<3000s(%) LT>3000s(%) Pearson Chi- 
Square (df) 
P value 
Aspirin Yes 129 (99.2) 22 (100) 0.17 0.68 
 No 1 (0.8) 0 (0)   
Clopidogrel Yes 128 (98.5) 22 (100) 0.34 0.55 
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 No 2 (1.5) 0 (0)   
Statin Yes 37 (84.1) 9 (100) 1.65 0.19 
 No 7 (15.9) 0 (0)   
ACE inhibitor Yes 99 (76.2) 17 (77.3) 0.01 0.90 
 No 31 (23.8) 5 (22.7)   
Beta blocker Yes 104 (80) 19 (86.4) 0.49 0.48 
 No 26 (20) 3 (13.6)   
Oral nitrate Yes 46 (35.4) 4 (18.2) 2.52 0.11 
 No 84 (64.6) 18 (81.8)   
Warfarin Yes 6 (4.6) 1 (4.5) 0 0.98 
 No 124 (95.4) 21 (95.5)   
PPI Yes 37 (28.5) 8 (36.4) 0.56 0.45 
 No 93 (71.5) 14 (63.6)   
Nicorandil Yes 11 (8.5) 1 (4.5) 0.39 0.52 
 No 119 (91.5) 21 (95.5)   
CCB Yes 30(23.1) 6(27.3) 0.18 0.66 
 No 100(76.9) 16(72.7)   
Insulin Yes 7(5.4) 1(4.5) 0.02 0.87 
 No 123(94.6) 21(95.5)   
Metformin Yes 11(8.5) 2(9.1) 0.01 0.92 
 No 119(91.5) 20(90.9)   
Clexane Yes 48(37.2) 13(59.1) 3.73 0.053 
 No 81(62.8) 9(40.9)   
Significance was taken as p<0.05, ACE inhibitor: Angiotensin converting 
enzyme inhibitor, CCB: Calcium channel blocker 
 
Table 6. Blood biochemistry on admission 
Blood test LT<3000s 
N, mean+/-SD 
LT>3000s 
N, mean+/-SD 
t (df) P 
Cholesterol 
(mmol/L) 
(N=109),  
4.25+/-1.93 
(N=18), 
4.34+/-1.4 
-0.19 (125) 0.84 
Creatinine 
(μmol/L) 
(N=130), 
112.72+/-
96.72 
(N=22), 
100.5+/-25.1 
0.58 (150) 0.55 
Hb 
(g/L) 
(N=130), 
14.72+/-9.58 
(N=21), 
13.44+/-1.5 
0.60 (149) 0.54 
HCT 
(%) 
(N=125), 
0.43+/-0.25 
(N=17), 
0.38+/-0.5 
0.76 (140) 0.44 
Troponin I 
(ng/ml)  
(N=129), 
4.64+/-14.8 
(N=22), 
13.65+/-24.6 
-2.35 (149) 0.02 
Platelet count 
(x109/L) 
(N=130), 
236.59+/-57.5 
(N=20), 
253.0+/-180.2 
-0.81 (148) 0.41 
RBC 
 
(N=128), 
4.58+/-0.5 
(N=21), 
4.42+/-0.55 
1.2 (147) 0.23 
Urea 
(mmol/L) 
(N=130), 
6.56+/-3.2 
(N=22), 
6.64+/-1.9 
-0.1 (150) 0.91 
Significance was taken as p<0.05, SD: standard deviation, normal values: 
haemoglobin is 130-180 g/L in adult males and 115-165 g/L in adult females; 
haematocrit is 40-52% in adult males and 36-47% in adult females; platelet 
count is 150-400x109/L; creatinine is 60-110 μmol/L in adult males and 45-90 
μmol/L in adult females; troponin I (at 12 hours from symptom onset) is <0.04 
ng/ml; total cholesterol is ≤4.0mmol/L. 
 
Table 7. Relationship between angiographic, interventional and 
echocardiographic characteristics with event occurrence. 
 
Characteristic Event 
N (%) 
No Event 
N (%) 
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1-vessel disease on 
angiography  
7 (7.9) 82 (92.1) 
2-vessel disease on 
angiography  
7 (15.6) 38 (84.4) 
3-vessel disease on 
angiography  
5 (27.8) 13 (72.2) 
Stent type (BMS) 8 (15) 43 (85) 
Stent type (DES) 9 (9) 88 (91) 
LV function (Normal) 11 (11) 84 (89) 
LV function (Mild impairment) 2 (13) 13 (87) 
LV function (Moderate 
impairment) 
3 (14) 19 (86) 
LV function (Severe 
impairment) 
3 (33) 6 (67) 
 
Significance was taken as p<0.05, angiographic result: x²(2)=5.97, p=0.05, 
stent type: x²(2)=1.48, p=0.47, LV function: x²(3)=3.33, p=0.34, 
LV function: left ventricular function (on echocardiography) 
 
In this sub-study we recruited 152 patients, the characteristics of which are 
outlined in tables 4-7. The extent to which patient characteristics varied by LT 
was evaluated.  On the basis of previous publications, identifying the LT value 
of 3000s as cut-off value for future event prediction (Saraf et al., 2010) (Sharma 
et al., 2012), patients were divided into 2 groups (LT<3000s, and LT>3000s).   
There was unintentional male dominance, with 120 male and 32 female 
participants, however no statistical significance was demonstrated on 
estimating the proportion and number of male and female participants with 
regards to the two LT groups [x²(1)=0.128, p=0.721]. Furthermore, no 
relationship was observed between age and LT (65+/-10 vs 64+/-11, p=0.761) 
or between any cardiovascular risk factor and LT. We then tested medications 
at the time of the baseline test, however no relationship was observed with LT.  
From all baseline biochemistry results, the only value showing statistically 
significant relationship with LT was the level of troponin. ACS patients with 
LT<3000s on GTT had a mean troponin I level of 4.6ng/ml, whereas patients 
with LT>3000s had mean troponin I level of 13.6 [t(149)=-2.35, p=0.02), which 
is a very important finding, confirming that delayed ET results in prolonged 
coronary flow occlusion by lasting thrombus, thus resulting in greater extend of 
myocardial damage. 
Furthermore, no relationship was observed between LT and future adverse 
events [x²(1)=0.759, p=0.382] or event type [x²(7)=7.37, p=0.391]. Also no cut-
off value for LT was found to be predictive of event occurrence [mean LT for 
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event 2018+/-1775 vs mean LT for no event 1738+/-1451, t(149)=0.765, 
p=0.446], but this can be explained by the small number of patients participating 
and subsequently the even smaller number of observed events, making 
extremely difficult to demonstrate statistically significant relationsip with LT. 
Finally, lysis time does not allow discrimination for events, as per  
ROC curve analysis (aoc=0.516, p=0.82). 
Despite demonstrating higher mean OT in patients with bleeding diathesis 
compared to patients without previous history of bleeding (506+/-289s vs 
447+/-156s), no statistical significance was found [t(149)=0.726, p=0.469]. 
Otherwise, no relationship was observed between the rest of clinical 
characteristics and baseline medication with OT. However, we did observe a 
relationship between both urea and RBC level with OT [Pearson correlation 
0.171, p=0.036 for urea, Pearson correlation -0.222, p=0.007 for RBC]. 
Furthermore, no difference was observed in mean value of OT between 
patients with events and patients with no events [460+/-134s vs 447+/-164s, 
t(149)=0.335, p=0.738]. Also, as per ROC curve analysis, OT does not allow 
for discrimination of events (aoc=0.46, p=0.6) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ROC curve (Lysis time by event). 
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ROC curve showing that LT is not a predictor of future adverse events 
 
Statistically, none of the baseline clinical characteristics, medications or 
biochemistry was associated with events. When we tested angiographic, 
interventional and echocardiographic characteristics, only the number of 
diseased coronary vessels was found to predispose to future events. In 
particular, as the number of diseased coronary vessel increased from 1 to 3, 
the likelihood of future event also increased from 7.9% (1VD) to 27.8% (3VD) 
[x²(2)=5.97, p=0.05].  
 
 
 
 
 
Discussion 
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The most important finding from the statistical analysis, is the proven 
relationship between ET and the level of troponin in ACS. Patients with 
LT<3000s had a mean troponin of 4.6ng/ml, whereas patients with LT>3000s 
had a mean troponin of 13.6ng/ml, which is much higher. In patients with 
delayed ET during ACS, lasting coronary thrombus can cause more extensive 
myocardial damage due to prolonged myocardial ischaemia, which is 
associated with a higher incidence of complications and mortality. Furthermore, 
patients who survive, have a higher degree of heart failure, which at the 
moment is not a treatable condition, it is associated with high mortality rates 
and patients can only have palliation for their symptoms. 
Despite the fact that we were not able to show statistical relationship between 
LT and future events, ROC curve analysis showed that there is a tendency 
towards this. Therefore, it is possible that a greater number of recruited 
patients, could have provided us with the result we aimed to show.  
 
On the other hand, and similarly to previous studies of global thrombosis, no 
relationship was observed between OT and future events. However, OT was 
evidently influenced by both the level of RBC and urea. A previous study has 
shown that RBC can cause aggregation in the form of rouleaux, a process that 
is still not fully understood, but can also activate the process of thrombosis, 
which under normal circumstances leads to homeostasis (Wagner, Steffen, & 
Svetina, 2013). Regarding urea level, in a previous study of global thrombosis 
(Sharma et al., 2012), we observed prolongation of OT in patients with end-
stage renal failure, in whom the levels of urea are very high, but our study has 
shown that this relationship still exists for lower levels of urea as well. 
 
Finally, statistical significance was observed between previous CAD and 
number of diseased coronary vessels with future event occurrence, which is 
expected, not only because it has been previously proven (Arbab-Zadeh, 
Nakano, Virmani, & Fuster, 2012), but also because statistically, it is expected 
that with more diseased coronary vessels there is a higher risk for coronary 
events. 
Proving once more the role of ET in CAD, reinforces our strong belief that 
further studies should be carried out, aiming at first to establish ET as a strong 
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predictor of future adverse events in patients with CAD and secondly to 
stimulate for further research for the development of pharmacotherapy 
enhancing ET, which will revolutionize the mode of treatment offered for 
primary and secondary prevention of CVD. 
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CHAPTER 5 
PAR-1 antagonist Vorapaxar and global thrombotic status in patients 
with coronary artery disease 
Background 
Current pharmacotherapy for patients with CAD aims to prevent platelet 
aggregation and subsequently thrombosis by deactivating TXA-2 and P2Y12 
adenosine diphosphate (ADP) receptor mediated platelet activation pathways. 
Although new antiplatelet regimens have proven to be fairly effective in 
reducing the occurrence of coronary events, they fail to prevent platelet 
activation through thrombin receptors, the role of which is very important in 
the process of thrombosis, therefore occurrence of thrombotic events is still 
possible (Gao, Zhao, & Li, 2015). All platelet activation finally results in 
thrombin generation, therefore inhibition of thrombin would be highly desirable 
to reduce thrombosis risk (Figure 1). Theoretically, concomitant use of 
thrombin receptor antagonists with other types of antiplatelet agents could be 
a very useful and promising pharmacological therapy for the prevention of 
acute coronary events. 
Vorapaxar is a novel, oral protease-activated receptor (PAR-1) antagonist that 
prevents platelet aggregation via thrombin inhibition. The role of this 
pharmacological agent was tested in the Thrombin Receptor Antagonist for 
Clinical Event Reduction in Acute Coronary Syndrome (TRACER) and Trial to 
Assess the effects of vorapaxar in Preventing heart attack and stroke in patients 
with atherosclerosis-Thrombolysis In Myocardial Infarction 50 (TRA2P-TIMI 50) 
studies (Leonardi et al., 2013) (David a. Morrow et al., 2012), in which our 
cardiac unit, at East and North Hertfordshire NHS Trust, participated as a 
recruiting centre and as investigators. Both were randomised double blind 
multicentre studies, comparing vorapaxar with placebo in patients with 
cardiovascular disease. 
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Figure 1. Antiplatelet activity of various pharmacological agents. 
 
 
The aim of TRA2P-TIMI 50 study, was to assess the effectiveness of adding 
vorapaxar to standard therapy, in patients with a history of MI, for secondary 
prevention of cardiovascular events (Cavender et al., 2015). 
In the TRA2P-TIMI 50 study, patients with established atherosclerosis in the 
form of MI or ischaemic stroke within the previous 2 weeks to 12 months or 
peripheral arterial disease with associated claudication and either ankle 
brachial index of <0.85 or previous revascularisation for limb ischaemia, were 
enrolled. Eligible patients were then randomly assigned to either receive a 
2.5mg oral tablet of vorapaxar or a placebo tablet, along with standard 
pharmacotherapy for their condition (Thrombolysis et al., n.d.) (Figure 2). 
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Figure 2. Summary of the TRA2P-TIMI 50 study 
 
 
The TRACER study, aimed to investigate whether use of vorapaxar, in addition 
to standard therapy would be superior to placebo in reducing the occurrence of 
recurrent ischemic cardiovascular events, as well as to determine its safety 
profile in patients with ACS, without ST-segment elevation (Tricoci et al., 2012). 
In the TRACER study, patients were enrolled following diagnosis of NSTEMI 
and symptoms of coronary ischaemia within 24 hours of hospital admission 
(Figure 3). For diagnosis of NSTEMI, patients should have exhibited at least 
one of the following biochemical and electrocardiographic features: rise in 
cardiac troponin or creatine kinase MB level above the upper normal limit, new 
ST-segment depression of more than 0.1mV or transient ST-segment elevation 
for less than half an hour of more than 0.1mV in at least two contiguous ECG 
leads. Furthermore, at least one of the following criteria was necessary: 
patients to be not younger than 55 years of age, to have had previous MI, PCI 
or CABG, DM or PVD. Following randomisation, patients received either 
vorapaxar or placebo, along with standard pharmacotherapy in a blinded 
fashion, once daily until the end of follow-up, after an initial loading dose of 
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40mg vorapaxar vs placebo, at least 1 hour prior to the coronary 
revascularisation procedure [(Thrombolysis et al., n.d.)]. 
Figure 3. Summary of the TRACER study. 
 
 
 
Aim 
Our sub-study aimed to investigate the potential influence of vorapaxar 
compared to placebo, on the thrombotic and thrombolytic status of each 
participant. 
 
Methods 
We obtained permission in the form of informed consent from 57 patients (42 
patients from the TRA2P-TIMI 50 and 15 from the TRACER study), in order to 
assess their thrombotic and thrombolytic status using the global thrombosis test 
(GTT), on and off treatment with the study medication (Thrombolysis et al., n.d.) 
. 
Participants were initially tested after at least 2 months in the study, and once 
more at least 1 month following discontinuation of the treatment. Baseline 
demographics collected and follow-up sessions were performed according to 
the TRA2P-TIMI 50 and TRACER study protocols. Furthermore, all study 
protocol and GTT blood tests, were performed by investigators blinded to study 
drug allocation (Thrombolysis et al., n.d.). 
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Following termination of the studies, we were informed about initial drug 
allocation, which enabled us to proceed to statistical analysis of the data 
collected for our study’s purposes (Thrombolysis et al., n.d.). 
We compared the LT and OT between the intervention and control groups and 
assessed them using the non-parametric Mann-Whitney U test. We considered 
treatment effect to be significant if the p value was found to be less than 0.05. 
We used the non-parametric Wilcoxon test in order to assess the significance 
of changes in OT and LT between periods on and off vorapaxar treatment. 
Mann-Whitney U test for continuous outcomes and two proportions Z-test for 
dichotomous outcomes were used to investigate differences between the 
clinical characteristics of the two groups, with p<0.05 considered as level of 
significance. 
Statistical analysis was carried out using the R and Stata software 
(Thrombolysis et al., n.d.) 
 
Results  
Patients receiving vorapaxar exhibited significantly longer OT whilst on 
medication, than off medication. They also exhibited significantly shorter LT 
whilst on medication, than off medication. Patients receiving placebo showed 
no difference in OT or LT, on and off treatment. During treatment, OT was 
longer, but LT was similar in the vorapaxar compared to the placebo patients. 
Following discontinuation of treatment, OT was similar in vorapaxar and 
placebo groups, but LT was longer in the vorapaxar group. LT was shorter in 
the placebo group whilst on treatment compared to LT on vorapaxar group off 
treatment. There was no difference in OT and LT between patients on TRA2P-
TIMI 50 and TRACER studies on both vorapaxar and placebo groups. 
 
 
 
 
 
 
Table 1. Results of thrombotic status using the GTT (Thrombolysis et al., n.d.). 
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 On treatment Off treatment P 
Vorapaxar 
group OT 
561s (422-654) 372s (338-454) 0.03 
Placebo group 
OT 
419s (343-514) 411s (346-535) 0.658 
Vorapaxar 
group LT 
1158s (746-
1492) 
1733s (1388-
2230) 
0.016 
Placebo group 
LT 
1236s (985-
1594) 
1400s (1092-
1686) 
0.524 
OT Placebo (on 
treatment) 
419s (343-514) 
vorapaxar 
(off treatment) 
372s (338-454) 
0.274 
LT Placebo (on 
treatment) 
1236s (985-
1594) 
vorapaxar 
(off treatment) 
1733s (1388-
2230) 
0.033 
Data are shown as median (IQR) 
OT: occlusion time, LT: lysis time, s: seconds 
 
 
 
Figure 4. OT in seconds, whilst on and off treatment, in vorapaxar and placebo 
groups (Thrombolysis et al., n.d.). 
 
 
 
 
 
 
 
 
 
Figure 5. LT in seconds, whilst on and off treatment, in vorapaxar and placebo 
groups (Thrombolysis et al., n.d.). 
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Table 2. Thrombotic status assessment using the GTT on and off treatment 
(Thrombolysis et al., n.d.). 
 
 Vorapaxar 
group 
Placebo group P 
OT (on 
treatment) 
561s (422-654) 419s (343-514) 0.09 
LT (on 
treatment) 
1158s (746-
1492) 
1236s (985-
1594) 
0.277 
OT (off 
treatment) 
372s (338-454) 411s (346-535) 0.079 
LT (off 
treatment) 
1733s (1388-
2230) 
1400s (1092-
1686) 
0.031 
Data are shown as median (IQR) 
OT: occlusion time, LT: lysis time, s: seconds 
 
 
 
 
 
 
 
Table 3. Thrombotic status assessment using the GTT in the two sub-groups, 
for TRA2P-TIMI 50 and TRACER (Thrombolysis et al., n.d.). 
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 TRACER TRA2P P 
V on treatment 
OT 
611s (498-649) 541s (379-608) 0.201 
P on treatment 
OT 
526s (381-608) 414s (342-493) 0.288 
V off treatment 
OT 
338s (298-374) 375s (362-479) 0.224 
P off treatment 
OT 
435s (370-595) 394s (340-506) 0.331 
V on treatment 
LT 
814s (688-1113) 1282s (756-
1788) 
0.161 
P on treatment 
LT 
1212s (1087-
1537) 
1260s (959-
1613) 
0.734 
V off treatment 
LT 
1946s (1585-
2278) 
1726s (1311-
2212) 
0.330 
P off treatment 
LT 
1394s (1002-
2337) 
1405s (1127-
1452) 
0.700 
 
Data are shown as median (IQR) 
V: vorapaxar, P: placebo, OT: occlusion time, LT: lysis time, s: seconds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
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This is the first time that an oral antiplatelet agent exhibits, apart from anti-
thrombotic properties (prolongation of OT), also demonstrated by other agents 
such as aspirin and clopidogrel on previous studies of GTT (Sharma et al., 
2012) (Saraf et al., 2010), enhancement of endogenous thrombolytic status  
(Thrombolysis et al., n.d.). It is not clear why vorapaxar has this effect on 
endogenous thrombolysis (ET), but a possible explanation would be the indirect 
reduction in thrombin generation, as a consequence of a stronger platelet 
inhibition mediated by the drug. 
In both TRA2P-TIMI 50 and TRACER studies, there was significant reduction 
in cardiovascular death, MI and stroke by vorapaxar. In TRA2P-TIMI 50, 
significant reduction was also observed in unstable angina and coronary 
revascularisation rate (Leonardi et al., 2013), results that are probably related 
to the antithrombotic properties of vorapaxar. In addition to the antithrombotic 
properties of vorapaxar, enhancement of ET, also exhibited in the vorapaxar 
arm of our sub-study, may be a very important mechanism of action of this drug. 
This is particularly important since shorter LT has been previously documented 
to be associated with reduction in the risk of MACE, as previously demonstrated 
in studies using the GTT for assessment of patients’ global thrombosis status 
(Sharma et al., 2012) (Saraf et al., 2010). 
On the other hand, in both TRA2P-TIMI 50 and TRACER studies, there was a 
higher incidence of bleeding in patients receiving vorapaxar. In a previous study 
(Saraf et al., 2010), median LT in 100 healthy volunteers was 1052s, and in our 
sub-study 22% of patients on vorapaxar had LT below this value, which 
suggests that enhanced ET may promote bleeding in patients receiving 
vorapaxar. Therefore, clinicians should be careful when prescribing a 
combination of antiplatelet agents, including vorapaxar, always taking into 
consideration potential benefits versus risks. In theory the ideal candidate 
receiving vorapaxar, should be someone with prolonged LT and subsequently 
higher risk of cardiovascular events, as traditional antiplatelet agents do not 
enhance ET, although this theory would need to be tested in clinical trials. 
Additionally, further studies should be carried out, in order to investigate what 
is a ‘safe LT range’ for avoiding bleeding, when treating patients with vorapaxar. 
For example, reducing LT from abnormally high levels to a normal range, close 
to the one found in normal volunteers mentioned earlier, rather than below this 
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level, could reduce the risk of bleeding, however, we should always take into 
account that at this level, LT may not prevent thrombotic events, making the 
decision for vorapaxar use, a two-edged sword. Theoretically, based on our 
knowledge from previous studies of global thrombosis, vorapaxar should be 
avoided in patients with prolonged OT (>300s) and very short LT (<1052s), as 
in theory it may not offer much benefit in improving thrombotic status, but might 
result in unprovoked bleeding. 
 
Another interesting point for discussion is the fact that none of the patients in 
our sub-study had prolonged LT, and this in combination with the fact that the 
number of participants was small, did not give us the opportunity to investigate 
the effect of the LT reduction on MACE. This is another reason why more 
studies are needed with greater number of participants. 
 
Another interesting finding of our sub-study, was the extent of rebound 
prolongation in LT and reduction in OT, following discontinuation of vorapaxar. 
Further studies should also be carried out in order to investigate changes in OT 
and LT following discontinuation of Vorapaxar, in order for us to understand 
what measures to take when discontinuation of this medication becomes 
necessary. For instance, stepwise discontinuation of vorapaxar may prevent 
profound changes in global thrombosis and possible complications that could 
be associated with it. 
 
We have identified a few limitations in our study. The first and main limitation is 
the small patient size, however, groups were well matched and randomly 
allocated. Secondly, the differing results observed in LT off treatment, in both 
placebo and vorapaxar groups, could be seen as a confounder to the study, 
however the fact that vorapaxar caused significant reduction in LT, strengthens 
the validity of our results. Thirdly the timing of the second blood sampling (off 
medication) made it just possible that since the half-life of vorapaxar is 
estimated at 187 hours, but at the time of the second blood sampling, one 
month following discontinuation of the medication, lasting anti-thrombotic 
and/or thrombolytic effects could still in theory be exerted. Finally, compliance 
was not confirmed with drug levels, so we had to rely on patients’ account and 
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statements with respect to medication adherence. 
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GENERAL CONCLUSIONS 
 
In this study, we have once more proven that endogenous thrombolysis (ET) 
can predict future events in patients with cardiovascular disease. In particular, 
we showed that delayed ET is associated with cardiovascular death within one 
year from PPCI. Furthermore, we showed that LT≥3000s is the cut-off value 
that predicts MACE, which coincides with the results of previous studies of 
global thrombosis. Even though the numbers were small, all STEMI patients 
demonstrating full or partial resolution of ST-segment elevation on ECG prior 
to PPCI, had very short LT and subsequently enhanced ET. None of these 
patients had any complications during their hospitalization period or had any 
future coronary events, which is a very interesting finding and definitely 
something that should be re-investigated in larger scale studies. 
Another important finding was the relationship between ET and troponin levels 
in NSTEMI patients. In patients with delayed ET, the mean level of troponin was 
significantly higher than in those with enhanced ET, meaning that lasting 
coronary thrombus in ACS, as a result of delayed lysis, is associated with more 
extensive myocardial damage and consequently with higher risk of 
complications and mortality. Unlike in other studies of global thrombosis, we did 
observe that increased thrombogenicity in the form of short OT, is associated 
with higher risk of non-fatal myocardial infarction and ischaemic stroke following 
PPCI.  
 
Balance between thrombogenicity and ET is the determinant of the outcome 
following an acute coronary event, therefore any imbalance can lead to 
complications. Future therapy for both primary and secondary prevention of 
CVD, should aim to promote this balance, therefore development of novel 
pharmacotherapy targeting ET is essential. We have discussed the role of 
PAR-1 antagonist vorapaxar and its observed effects in lowering LT, thus 
enhancing ET, apart from its antiplatelet properties. However, usage of agents 
like vorapaxar would only be beneficial once establishment of ‘safe limits’ of OT 
and LT is achieved, for maintenance of the balance between thrombosis and 
thrombolysis and prevention of bleeding. 
 112 
 
Current guidelines suggest fixed antiplatelet agent administration for primary 
and secondary prevention of CVD. However, thrombogenicity and ET vary 
among different individuals, therefore in the future, tailored pharmacotherapy 
could be provided, depending on the global thrombosis status of each patient, 
aiming to identify patients at high risk of thrombosis and bleeding. For this to 
be achieved, a platelet function test, such as the GTT, could be routinely used 
for patients receiving primary and secondary prevention treatment. However, in 
order for GTT to be established as a consistently accurate and safe screening 
test, larger studies confirming its value should be carried out. At present, the 
GTT cannot be a part of the management of CVD, as it has not been validated 
in large-scale trials. However, once its true value is proven in the future and 
subsequently its usage is approved for primary and secondary prevention of 
CVD, we strongly believe that has the potential to revolutionize future 
management of this condition for the benefit of millions of people worldwide. 
 
 
 
